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CHAPTER I
INTRODUCTION
Overview
The development of a blood substitute is a significant medical need as blood
shortages have become more common in this current decade and pathogens, such as
HIV, pose risks for blood transfusions, limiting the amount of blood available in
some parts of the world. Due to the world’s demand for blood, the development of
hemoglobin-based oxygen carriers (HBOCs) has been an active area of research the
last thirty years. An ideal oxygen carrier would deliver oxygen, be disease free, lack
immunosuppressive effects, would not need blood typing, be available at a
reasonable cost, and have minimal, if any, side effects (Ness and Cushing 2007; Sakai
et al. 2000).
The difficulties in producing an ideal oxygen carrier result from
complications affiliated with the effects of HBOCs once administered during clinical
trials. During the past decade, approaches to develop a HBOC utilizing polyethylene
glycol (PEG) have been frequently used. Conjugation of PEG chains onto proteins has
been a growing area of research due to the ability of PEGylated proteins to improve
therapeutic potentials by camouflaging the proteins from the immune system. PEG
also reduces glomerular filtration of the complexes from the body

1

(Bailon and Berthold 1998; Harris and Chess 2003; Roberts, Bentley, Harris 2002).
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PEGylation has been used in HBOCs to counteract some of the unfavorable side
effects, such as low retention times of HBOCs in vivo, NO scavenging of the Hb, and
the vasoconstrictive side-effects due to NO scavenging (Doherty et al. 1998;
Muldoon et al. 1996). Several PEG-HBOCs have reached clinical trials, but none have
been approved for use in the United States. This review chapter outlines current
statuses of the development of PEGylated Hb compounds and suggests some
potential modifications that might improve their ability as potential HBOCs.
Sites of PEGylation and Variations of PEG
Attaching PEG chains onto a protein can be accomplished by an assortment
of reactions. Different linking groups on the PEG molecule can achieve PEGylation at
a variety of amino acid residues within the Hb tetramer. The first attempt at the
PEGylation of Hb was done via urethane likages (Fig. 1) by Enzon resulting in 10
copies of PEG-5K chains conjugated onto a single bovine Hb tetramer (Acharya et al.
2011). In order to simplify the PEGylation method and produce a more cost
effective protocol, Extension Arm Facilitated (EAF) PEGylation was developed at
Albert Einstein College of Medicine by Acharya and coworkers (Acharya and and
Manjula 2006; Manjula et al. 2005). This form of PEGylation involves the thiolation
of the tetramer using a heterobifunctional reagent to produce a thiol functional
group that is later used to attach PEG chains onto the desired protein using a
complementary functionalized PEG (Acharya et al. 2011; Acharya and and Manjula
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2006; Manjula et al. 2005). EAF-PEG has little impact on the Hb tetramer stability of
the PEG-Hb product, in direct contrast from direct PEGylation that destabilizes the
quaternary structure of the PEG-Hb tetramer (Manjula et al. 2005). HexaPEGylated
Hb’s generated by direct PEGylation exist primarily as Hb dimers, and the same was
found with EAF-PEGylation (Hu et al. 2007; Li et al. 2008). Various types of EAFPEGylation techniques have emerged, including the use of propionamide,
propylamine, and thiosuccinimido phenyl linkages (Fig 1.) (Li et al. 2008). This list is
not exclusive since the production of a thiol functional group can be created in
numerous ways, but Figure 1 includes some of the common techniques currently
employed for Hb PEGylation.
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Figure 1. Schematic representation of the linkages in the PEGylated Hbs generated
by EAF PEGylation, acylation chemistry and reductive alkylation mediated
PEGylation shown by Li et al. The abbreviation “PEG” can be of varying lengths and
a general schematic is listed first. For the EAF PEG linkers listed above, the linker
type is first followed by its application (listed in parentheses or brackets)(Li et al.
2008).

The common sites of PEGylation on Hb are on various Lys residues modified
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into thiol groups using Traut’s reagent. Li et al. determined the frequency of
modification (Table 1). The modified lysines were: Lys-8 (), Lys-11 (), Lys-56 (),
Lys-90 (), Lys-95 (), and Lys-132 () (Li et al. 2008). In addition, the free amino
groups of the N-terminal Val residues of both chains were also PEGylated after
reaction with Traut’s reagent (Li et al. 2008). PEGylation at these N-terminal sites
destabilized the Hb tetramer (Hu et al. 2012). This may be attributed to the
insertion of the PEG into the α dimer interface, dissociating the tetramer (Li et al.
2008).
Table 1. Identification of the sites of PEGylation in PEGylated Hb with corresponding
P50 and Hill Coefficient (n) values as determined by Li et al. (Li et al. 2008).
Residues
Val-1(α)
Val-1(β)
Lys-8(β)
Lys-11(α)
Lys-56(α)
Lys-90(α)
Lys-95(β)
Lys-132(β)

Percent Modification in PEGylated Hbs (P50/n)
HexaPEGylated Hb
OctaPEGylated Hb
DecaPEGylated Hb
(10.8/1.9)
(8.5/2.1)
(8.0/2.0)
48
80
100
36
48
64
27
33
45
37
46
56
44
56
67
38
42
54
20
31
58
35
44
57

*All PEGylated Hbs were modified via Propionyl-PEG 5kDa
*P50 values are reported in mm Hg; n, Hill Coefficient

In addition to the N-terminal Val residues, there are other sites on the Hb
tetramer that should be avoided during PEGylation. Conjugation of PEG on Cys-93
() has been studied to determine the effect on Hb functionality. Li and coworkers
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demonstrated that Cys-93 () could be reversibly protected using 4,4dithiodipyridine (4-PDS) (Li et al. 2009). Consequently, EAF-PEG complexes were
made with both protected and unprotected Hb’s (Figure 2) (Li et al. 2009; Wang et
al. 2014). Compared to native Hb, PEGylation at the Cys-93 () residue produced a
higher oxygen affinity, a lower Hill coefficient, an increased autoxidation rate, and a
greater rate loss of the heme group (Hu et al. 2008; Li et al. 2009; Manjula et al.
2003). Further oxygen binding studies by Li, Acharya, and colleagues, however,
determined that avoiding PEGylation of Cys-93 () had a limited influence on
oxygen affinity if the Hb was previously modified to keep it in a high oxygen affinity
state or was unmodified entirely. The increased oxygen affinity observed in EAFPEG Hb can be a consequence of Hb PEGylation at other sites, rather than
modifications at Cys-93 (). However, modification of the Cys-93 () residue does
result in a high oxygen affinity hemoglobin (Abraham, Phillips, Kennedy 1983; Li et
al. 2009).

7

Figure 2. Schematic representation of the extension arm facilitated PEGylation of Hb
with reversible protection of Cys-93 () performed by Li et al. It should be noted
that PEGylation is shown on an alpha subunit of Hb but can occur on a subunit with
an exposed Lys residue (Hu et al. 2012).
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PEGylation on the Cys-93 () residues might be advantageous as it reduces
the ability of Hb to scavenge NO in vivo. Kluger and co-workers found that PEGylated
Hb created by this site specific modification produced NO at the heme faster than
that of the native hemoglobin or non-PEGylated T state crosslinked hemoglobin
(Lui, Dong, Kluger 2008). They proposed that the higher NO production was
resultant from an increased stability of R state hemoglobin produced by PEGylation
(Lui, Dong, Kluger 2008). The number of PEG chains attached to the hemoglobin
tetramer did not appear to correlate with heme-nitrite reactivity so long as one PEG
chain is conjugated specifically to the Cys-93 () residue. It was also found that
heme-nitrite reactions within Hb conjugated with two PEG chains were comparable
to Hb modified with six PEG chains (Lui, Dong, Kluger 2008). Lui et al. used a tetrafunctional crosslinker to link two hemoglobin tetramers together for stability,
followed by PEGylation on the Cys-93 () residues on each hemoglobin tetramer.
This resulting product was found to be non-hypertensive when administered into
mouse models (Lui et al. 2012).
Number of PEG Chains Attached to Hemoglobin and the Resulting Size
Modification
The residues on which Hb can be PEGylated have been identified, but this
does not imply that all the sites are PEGylated during every procedure. Depending
on the reagent used, Hb can be PEGylated between two to ten sites (Li et al. 2008).
Acharya and co-workers found that a twenty, forty, or eighty fold excess of
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Propionyl PEG to Hb resulted in Hexa-, Octa-, or Deca-PEGylated Hb, respectively (Li
et al. 2008). Enzon created this DecaPEGylated bovine Hb (Acharya et al. 2011),
which was one of the first attempts at a PEG-Hb nanoparticle. Further studies and
the development of thiolation-mediated EAF-PEGylation produced a HexaPEGylated oxy-Hb. In doing so, it was found that this was an optimal PEGylation
reaction since all of the Hb tetramers were fully PEGylated (Acharya, Manjula, Smith
1996; Manjula et al. 2005). Table 1 shows the percentage of PEGylation at specific
residues per Hb tetramer for the Hexa-, Octa-, or Deca-PEGylation species. The P50
and n values for each PEGylated Hb (Table 1) show that while it is possible to
produce a higher level of PEGylation on Hb, it is not necessary since the oxygen
binding properties did not change significantly (Li et al. 2007).
In addition to controlling the quantity of PEG chains attached to the protein,
the length of the chains can also vary. Acharya and colleagues investigated PEG
chains of weights in the 2-20 kDa range (Acharya et al. 2011; Hu et al. 2008; Li et al.
2008). The most commonly used PEG weight is 5 kDa, but it has not been elucidated
that it is more advantageous than the 3 kDa PEG for usage in a blood substitute
(Vandegriff and Winslow 2009). PEGylated proteins exhibit an apparent molecular
mass that is higher than the molecular weights of the protein and PEG chains
combined. This is a result of the PEG chains creating a hydration shell around the
protein that increases the hydrodynamic volume (Portoeroe et al. 2008; Vandegriff
et al. 2003). The hydrodynamic volumes of various HexaPEGylated-Hbs have been

determined by size exclusion chromatography (SEC) coupled with dynamic light
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scattering (DLS) (Li et al. 2008). Compared to native Hb (Table 2), PEGylated Hb
showed a volume increase from eight to twelve fold, depending on the PEG
decoration attached (Li et al. 2008). PEG chains create a shell around the Hb
tetramer, increasing the particle volume (Figure 3). This is of relevance to blood
substitutes because an increased volume should counteract the NO scavenging and
reduce vasoconstriction (Palmer and Intaglietta 2014). Cooper proposed an
increased hydrodynamic volume as a protection mechanism against NO scavenging,
otherwise made permissible by a HBOC’s small size. A smaller total volume HBOC
enables the tetramer to move closer to the arterial wall, where NO can be scavenged,
leading to vasoconstriction (Cooper 2009). A total PEG mass of around 30 kDa may
not suffice to counteract vasoactivity of a PEG-Hb polymer but a total mass of
around 50 kDa may be sufficient to decrease NO scavenging (Rohlfs et al. 1998).
Table 2. Influence of intramolecular α crosslinking on hydrodynamic volume,
oxygen affinity and Hill Coefficients of PEGylated Hbs (Hu et al. 2007; Li et al. 2008).
Sample
HbA
αα-fumaryl Hb
(Propionyl-PEG5K)6-Hb
(Propionyl-PEG5K)6- αα-Hb
(Propyl-PEG5K)6-Hb
(Propyl-PEG5K)6- αα-Hb
(SP-PEG5K)6-Hb
(SP-PEG5K)6- αα-Hb

Volume (nm3)
125
125
860
1375
659
1204
950
1047

P50 (mm Hg)
13.5
30.5
10.0
18.0
6.3
16.0
7.0
9.9

*P50 values are reported in mm Hg; n, Hill Coefficient

Hill Coefficient (n)
2.8
2.4
1.9
1.5
1.9
1.5
2.2
1.7
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Figure 3. A pictorial representation of hexaPEGylated αα-fumaryl Hb. It has an
internal protein shell with a molecular diameter of 6 nm and an outside shell with a
molecular diameter of 14 nm. An intermediate protein hydration layer is
sandwiched between the two shells. The thickness of this layer and the electrostatic
interactions within this layer are expected to be dictated by the chemistry and site
selectivity of the PEGylation. The two regions of the molecule differ significantly in
the density. The outside PEG shell of medium density is filled loosely with PEG
molecules (Li et al. 2008).

Analysis of PEGylated Crosslinked Hemoglobin
One of the first attempts at creating a HBOC was to use stroma free Hb that
had been crosslinked in order to maintain the Hb tetramer integrity. Unstable
stroma free Hb can dissociate into -dimers that are small enough to be excreted

by the kidney (Bunn, Esham, Bull 1969; Chan et al. 2000). Bis(3,5 dibromosalicyl)
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fumarate (DBSF) crosslinks -amino groups of Lys821 and Lys822 under oxy
conditions, producing a Hb with high oxygen affinity and increased stability (Fig. 4)
(Walder et al. 1979; Walder, Walder, Arnone 1980; White and Olsen 1987; Yang and
Olsen 1991; Zaugg et al. 1980). If this same reaction is done with deoxy-Hb,
crosslinking occurs between Lys991 and Lys992 residues. This product exhibits a
low oxygen affinity but increased stability (Fig. 4) (Chatterjee et al. 1986; Highsmith
et al. 1997; Snyder et al. 1987; Tye et al. 1983; Yang and Olsen 1991).
Crosslinking demonstrates an ability to stabilize the Hb tetramer. When
PEGylation procedures were first developed, the stability of the Hb tetramer was a
concern. Initially, PEG conjugation, not EAF-PEG conjugation, occupied the center of
the Hb tetramer and displaced the water molecules within the central cavity
between the Hb -dimers (Caccia et al. 2009; Hu et al. 2007; Hu et al. 2009; Hu et
al. 2011). As a result, the Hb became less stable and split into two -dimers. This
dissociative effect could be minimized by cross-linking the tetramer prior to
PEGylation (White and Olsen 1987).
From a structural point of view, it was suggested that upon crosslinking,
stress originally present at the 11 interface induced by PEGylation was
significantly reduced in comparison to non-crosslinked PEGylated hemoglobin (Hu
et al. 2007). It was also noted that the heme environment was slightly perturbed
when crosslinking and PEGylation were not used in combination. It is thought that

heme agitation in PEGylated -fumaryl crosslinked hemoglobin is significantly
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reduced as a result of an increased stability between the  interface (Hu et al.
2007). Winslow, Acharya, and their respective laboratories found that (propylPEG5K)6--Hb compared to (propyl-PEG5K)6-Hb exhibited a significantly
enhanced molecular volume and a lower colloidal osmotic pressure (COP) (Hu et al.
2007; Winslow 2003). This lowered COP makes it possible to use a HBOC solution of
higher concentrations in clinical trials, which allows for a higher rate of oxygen
delivery to tissues in the body that addressed an early limitation of PEGylated
hemoglobins (Hu et al. 2007) . It has been found that PEGylation, in conjunction with
crosslinking regardless of oxy or deoxy conditions, increases hemoglobin’s affinity
for oxygen, creating a situation that favors oxygen delivery to hypoxic tissue. In
summary, PEGylation and crosslinking should not be mutually exclusive techniques
in the production of a HBOC. Rather, they should be used in conjunction to
counteract some of the unfavorable side effects produced by the individual
techniques.
The Effects of PEGylation on Hemoglobin’s Oxygen Affinity/P50 and
Cooperativity
A major challenge in HBOC production has been adjusting the oxygen binding
properties. Within a red blood cell, a homeostatic environment allows hemoglobin
to maintain its allosteric cooperativity. This allows the RBC to release its bound
oxygen efficiently in peripheral tissues. A P50 of 26 mm Hg is established by pH

control inside the RBC along with the presence of 2,3-bisphosphoglycerate (2,3-
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BPG). This results in Hb’s characteristic sigmoidal oxygen binding curve. A problem
that arises is that most HBOC production utilizes stroma free Hb. Once the protein is
extracted from the RBC, the P50 value drops from 26 mm Hg to around 13.5 mm Hg
(Tables 2 and 3) (Hu et al. 2007; Li et al. 2008; Li et al. 2009; Meng et al. 2014). As a
result, variations in crosslinking procedures, in conjunction with variations of EAFPEG chains conjugated to the protein, have been studied in attempts to circumvent
the dramatic decrease in the P50 value.
Using DBSF as a crosslinker under oxy-conditions links the -monomers,
favoring the R state conformation (Fig. 4). This reaction at the Lys-82() residues
results in a Hb with higher oxygen affinity (Table 3). However, crosslinking with the
same reagent under deoxy-conditions creates a lower oxygen affinity Hb (Table 3)
by linking the  subunits, favoring the T state conformation (Figure 4). PEGylation
always increases the oxygen affinity of Hb (Table 3), whether it is stroma free Hb, 
crosslinked Hb, or  crosslinked Hb (Hu et al. 2007; Li et al. 2008; Li et al. 2009;
Meng et al. 2014). The type of EAF linker used does affect the oxygen affinity. For
example,  crosslinked Hb modified with six propionyl PEG5K chains has a P50 of
22.8 mm Hg whereas  crosslinked Hb modified with six propyl PEG5K chains has a
P50 of 16.0 mm Hg (Highsmith et al. 1997; Hu et al. 2007). Protecting the Cys-93(β)
residue allows production of a modified Hb tetramer with a lower oxygen affinity
(Table 3). However, the effects of PEGylation on the tetramer still produce a higher

oxygen affinity Hb. This is resultant from the Cys-93(β) residue being exposed
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instead of buried in the Hb tetramer in the R state. Thus, any modifications on this
site increase the oxygen affinity of the Hb tetramer by keeping it predominantly in
the R state (Abraham, Phillips, Kennedy 1983).

Figure 4. This is a standard crosslinking reaction that utilizes DBSF (a fumaryl
crosslinker) to modify Hb. Under oxy-conditions ( crosslinking) crosslinking occurs
between the two 99 lysine residues and under deoxy-conditions ( crosslinking)
crosslinking occurs between the two 82 lysine residues.
*It should be noted that crosslinking occurs within the central cavity of the Hb
tetramer.
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Along with altering the P50 values, crosslinking and PEGylation play a role in
shifting the Hill coefficient (n). Hemoglobin, whether within RBCs or stroma free,
has a Hill value around 2.8, but once modified, this value decreases, indicating a
decrease in cooperativity (Table 3)(Hu et al. 2007; Li et al. 2008; Li et al. 2009; Meng
et al. 2014). Upon PEGylation, the Hill coefficients of all forms of Hb decrease
further. Crosslinking and PEGylation restrict the movement of the Hb tetramer,
relative to unmodified Hb, decreasing its cooperativity.

Table 3. Influence of intramolecular crosslinking (α, and ) and EAF PEG styles on
oxygen affinity and Hill Coefficients (n) (Hu et al. 2007; Li et al. 2008; Meng et al.
2014; Wang et al. 2014).
PEGylated Hb Sample
HbA
αα-Hb
ββ-Hb
(Propyl-PEG5K)6-Hb
(Propyl-PEG5K)6- αα-Hb
(Propyl-PEG5K)6- ββ-Hb
(Propionyl-PEG5K)6-Hb
(Propionyl-PEG5K)6- αα-Hb
(Urethane-PEG5K)6-Hb
(Urethane-PEG5K)6-αα-Hb
EAF-PEG-Hb without free Cys-93(β)
EAF-PEG-Hb with free Cys-93(β)
EAF-PEG-αα-Hb without free Cys-93(β)
EAF-PEG-αα-Hb with free Cys-93(β)

Oxygen Affinity
P50 (mm Hg)
Hill Coefficient (n)
13.5
2.8
30.5
2.4
6.3
2.1
6.3
1.9
16.0
1.5
5.9
1.9
10.0
1.8
22.8
1.8
8.0
2.0
23.3
2.1
6.9
2.1
8.5
2.0
9.9
1.7
18.5
1.7

*αα-Hb=αα-fumaryl crosslinked Hb; ββ-Hb= ββ-intramolecular succinimidophenylPEG2K crosslinked Hb
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PEGylation and its Success: Hemospan, Functional Universal Red Blood Cells,
and Polynitroxylated PEGylated Hemoglobin
Hemospan, also known as MP4, was created by Sangart via site-specific
PEGylation chemistry that attached seven to eight 5 kDa maleimide-activated PEG
chains to a single human  crosslinked hemoglobin tetramer (Vandegriff et al.
2008). Hemospan injected into rat and mouse models along with humans was not
shown to induce vasoconstriction, but unfortunately, its oxygen delivery was
minimal as demonstrated by the reported P50 value of 5 mm Hg (Tsai et al. 2003;
Vandegriff et al. 2003; Vandegriff and Winslow 2009). This low P50 value possesses
some beneficial characteristics including a capacity to deliver oxygen to highly
hypoxic tissues within humans. However, for overall oxygen delivery in vivo, the P50
value (5 torr) is too low to use outside of oxygen delivery to dramatically hypoxic
tissues Fortunately, MP4 does not induce vasoconstriction (by proxy, hypertension),
and there was no gastrointestinal discomfort observed in subjects during Phase I
and II clinical studies beginning in 2002 (Bjorkholm et al. 2005; Vandegriff and
Winslow 2009). Furthermore, MP4 even progressed to Phase III clinical trials in
Europe in attempts to assess its safety in controlled clinical orthopedic surgeries
(Vandegriff and Winslow 2009).
In 2007, Acharya and colleagues employed PEGylation for the creation of a
universal red blood cell derived from human blood (Nacharaju, Manjula, Acharya
2007). Two PEGylation methods were used. In the first method, free amino groups

on red blood cell (RBC) membrane proteins were converted into exposed thiol
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groups using Traut’s reagent. These thiols were then modified with a maleimidePEG (Mal-Phe-PEG), with an optional second step of acylation chemistry-mediated
PEGylation that attached a succinimidyl propionate-PEG (SPA-PEG) to amino groups
on membrane proteins of the RBC (Nacharaju, Manjula, Acharya 2007). The first
option for PEGylation yields a product that contains an extension arm produced
from intermediate steps while the second option does not produce an extension arm
between a membrane protein and the PEG chain. Differences were also seen
between these two forms of PEGylated RBCs. It was found that the direct
conjugation of PEG chains to RBC membrane proteins via SPA-PEG 5 kDa did not
mask the D antigen (responsible for Rh +/- blood group) like the RBC that had EAFPEG modified proteins (Mal-Phe-PEG 5kD) (Nacharaju et al. 2005; Nacharaju,
Manjula, Acharya 2007). Unfortunately, the small molecular size of the 5 kDa PEG
chains was unable to mask the Rh system that accompanies blood typing unless an
EAF PEGylation method is utilized. It is speculated that this phenomenon is
permitted because Rh system antigens are multi-pass-transmembrane proteins with
antigentic epitopes that are very close to the cell membrane and that even these
small PEG chains are too bulky to react with the Rh antigen protein’s amino groups
(Avent and Reid 2000; Bradley et al. 2002; Fisher and Armstrong 2002; Nacharaju,
Manjula, Acharya 2007). In regards to masking the A antigen, it was found that it
could only be achieved by subjecting the RBCs to a two phase PEGylation system by

first attaching 5 kDa PEG chains followed by the attachment of 20,000 kDa PEG
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chains (Nacharaju et al. 2005). The ABO blood type system antigens are
carbohydrates located off membrane lipids and proteins and extend out into the
solvent phase. Therefore, in order to mask them, bigger PEG chains were needed
(King 1994; Reid and Mohandas 2004). The research of Acharya and coworkers
showed that regardless of which antigen A, B, or D was meant to be masked by this
two-step PEGylation procedure, it did not matter whether or not EAF PEGylation
was utilized because antigen masking was achieved regardless of PEGylation
method (Nacharaju et al. 2005; Nacharaju, Manjula, Acharya 2007). Only RBCs
PEGylated via thiolation mediated PEGylation exhibited an increased oxygen affinity
while those done with SPA-PEG had comparable oxygen affinities to that of
unmodified erythrocytes (Nacharaju, Manjula, Acharya 2007). It was concluded that
a two-phase PEGylation procedure, Mal-Phe-PEG 5 kDa followed by SPA-PEG 20
kDa, would be most effective for masking A, B, and D antigens while having minimal
influence on the RBCs oxygen binding affinity (dropping the P50 from 27.5 to 22.5)
(Nacharaju, Manjula, Acharya 2007).
SynZyme Technologies created a novel HBOC, incorporating PEGylation and
nitroxylation techniques to modify a Hb tetramer, called Polynitroxylated PEGylated
Hemoglobin (PNPH) (Carleton, Hsia, Ma 2012). The product is a modified bovine Hb
with 12-14 nitroxides and 8-10 PEG conjugations (Carleton, Hsia, Ma 2012; Lewis
and Ross 2014; Shellington et al. 2011). The added nitroxides mimic the effects of

superoxide dismutase (SOD), present in a RBC, reducing oxidative stress by
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quenching reactive oxygen species (ROS) that are toxic to cells (Buehler et al. 2004;
Lewis and Ross 2014). PNPH’s effects were examined in mice models to assess their
neurotoxicity, and ability to attenuate fluid requirements in traumatic brain injury
(TBI) with hemorrhagic shock (HS) (Brockman et al. 2013; Lewis and Ross 2014;
Shellington et al. 2011). PNPH was found to not be cytotoxic to neurons in areas of
the hippocampus and was found post TBI with HS that there was significantly lower
brain edema in mice treated with PNPH compared to those treated with lactated
Ringer’s (LR) solution (Brockman et al. 2013; Shellington et al. 2011).
Unfortunately, PNPH has a high oxygen affinity (P50 10 mm Hg), indicating it will
mainly deliver oxygen to severely hypoxic tissue (Lewis and Ross 2014; Shellington
et al. 2011). The SOD-mimetic abilities of PNPH make it unique from all other
previous PEG based HBOCs, however the low P50 is a major concern for delivering
oxygen during HS or trauma situations.
With these HBOCs, a clear disadvantage is that MP4 and universal RBC’s
utilize human hemoglobin (or human RBCs) to create the final product, while MP4
and PNPH have a very high oxygen affinity. While this may provide useful
compounds that have potentially beneficial applications, all of these products do not
address the need for a blood substitute independent of human blood donations. In
addition, PEG RBCs would have the same storage problems as normal RBCs and
while it is universal donor it is not a stable product.

Conclusions
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An effective HBOC would be useful in trauma and other medical situations.
Blood transfusions require disease free and properly type matched blood. This
problem is exacerbated when blood donations are low, coupled with the short shelf
life of donated blood. To counteract these complications, a PEGylated HBOC should
be derived from non-human hemoglobin sources, universal for all types of blood,
have a longer shelf life compared to donated whole blood, and be disease free.
Review of the literature suggests that a larger molecular size HBOC, comparatively
to the size of stroma free hemoglobin, is required to be successful in vivo. In
addition, the HBOC should not dissociate into dimers, possess no nephrotoxicity,
and should not scavenge NO from the endothelial tissue of the cardio vascular
system. PEGylated hemoglobin has a larger hydrodynamic volume than native Hb
and has shown to produce NO instead of removing it from living systems depending
on the site of conjugation the PEG chains. Ideally, a PEGylated HBOC will be able to
be lyophilized for longer storage. It has already been shown that PEGylation
improves the stability of a PEGylated protein when it is reconstituted in liquid post
lyophilization (Heller, Carpenter, Randolph 1999). In conclusion, a successful PEG
based HBOC will have an increased size, contain extension arm facilitated PEG (EAFPEG) to not disrupt the Hb tetramer interface, be crosslinked to avoid Hb tetramer
dissociation, and be derived from a non-human source.

CHAPTER II
STATEMENT OF RESEARCH
Blood transfusions require disease free and properly type matched blood.
This becomes a problem when blood donations are at an all-time low coupled with
the fact that the shelf life of donated blood is relatively short lived. Furthermore,
there are areas of the world where clean blood is difficult to come by. To counteract
these complications a blood substitute should be derived from non-human hemoglobin sources that is universal for all types of blood, have a longer shelf life compared to donated whole blood, and be disease free. If this problem were solved, it
would relieve a myriad of problems within the current medical community and
blood donation system. Review of the literature suggests that a larger molecular size
HBOC, comparative to the size of stroma-free hemoglobin, is required to be successful in vivo. In conjunction with the aforementioned characteristics, a HBOC needs to
not dissociate into hemoglobin dimers, possess no nephrotoxicity, and it should not
be able to scavenge NO from the endothelial tissue of the cardiovascular system.
PEGylated hemoglobin has a larger hydrodynamic volume and is immunogenic
compared to native hemoglobin. In the end, a successful PEG based HBOC will have
an increased size, crosslinked to avoid tetramer dissociation, be unable to scavenge
NO, and be able to deliver oxygen to tissues.
22

The first part of this novel research crosslinks (XL) bovine hemoglobin in a
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high oxygen affinity state ( XL-Hb). After crosslinking, the XL-Hb is covalently attached to an eight arm maleimide PEG backbone via the Cys-93 () residue. This
methodology covers a PEG back bone in multiple Hb tetramers. This methodology is
the reverse of traditional PEGyaltion and thus has been called “inside-out” PEGylation. The hemoglobin is extracted from whole bovine blood, so there is no need for
human donations, and the crosslinking procedure will prevent the hemoglobin from
dissociating into dimers in vivo. In addition, the site of conjugation on the Cys-93 ()
has been found to be favorable in reducing NO scavenging from endothelial tissue
making it an ideal site for conjugation of the PEG backbone. The second part of the
research crosslinks bovine Hb in a lower oxygen affinity state ( XL-Hb). After, the
XL-Hb is activated with an alkyne by an NHS ester. The alkyne is able to react with
an eight arm azide PEG by strain promoted azide-alkyne click chemistry. This form
of inside-out PEGylation yields a lower oxygen affinity Hb polymer compared to the
previously mentioned methodology. Finally the large size of the polymers should
assist in reducing its ability to scavenge NO.
A universal HBOC for every medical situation does not have to exist. Variations amongst HBOCs oxygen affinity would allow medical providers to prescribe a
proper HBOC for a given circumstance. Based on these considerations I have produced a high and a low affinity PEG XL-Hb polymer that are intended to be used in
lieu of blood transfusions.

CHAPTER III
“INSIDE-OUT” PEGYLATION OF BOVINE -CROSSLINKED HEMOGLOBIN
Chapter Introduction
Human blood transfusions are the only viable way to rapidly replace lost
blood in a patient while delivering oxygen to tissues. Transfusions have limitations
due to risks affiliated with blood borne pathogens, the limited shelf life of donated
blood, immunogenic responses, hemolytic transfusion reactions, and a dependence
on human donation (Jahr et al. 2011). Stroma-free hemoglobin (Hb) is not a viable
replacement because of tetramer dissociation in circulation, leading to rapid
filtration by the kidneys and subsequent nephrotoxicity. It is also capable of
scavenging nitric oxide which induces vasoconstriction leading to increased
peripheral vascular resistance and subsequent organ dysfunction (Doherty et al.
1998; Muldoon et al. 1996; Reid 2003). These problems have shown the need for a
viable alternative. An ideal hemoglobin-based oxygen carrier (HBOC) would
efficiently deliver oxygen to tissues while being pathogen free, universal for all
blood types, non-immunogenic, and available at a minimal cost while possessing a
long shelf life with minimal refrigeration (Estep et al. 2008; Ness and Cushing 2007;
Reid 2003; Sakai et al. 2000). While crosslinking (XL) the Hb tetramer prevents
dissociation, tetramers solely modified by crosslinking failed as HBOCs due to
24
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damage to the vascular tissue and NO scavenging (Ness and Cushing 2007; Reid
2003; Sakai et al. 2000).
To counteract these problems previous HBOC design has produced bistetrameric Hb polymers, liposome encapsulated Hb nanoparticles, Hb
microparticles, and polyethylene glycol (PEG) Hb conjugates (Agashe and Awasthi
2009; Bradley et al. 2002; Lui et al. 2012; Singh et al. 2015; Xiong et al. 2012).
Recent reviews have shown that conjugation of PEG to Hb has been one of the more
successful methods thus far (Jahr, Akha, Holtby 2012; Palmer and Intaglietta 2014).
Protein PEGylation has been shown to improve therapeutic potential by
camouflaging the proteins from the immune system and reduce glomerular
filtration from the body (Bailon and Berthold 1998; Harris and Chess 2003; Roberts,
Bentley, Harris 2002). Several approaches exist to PEGylate Hb. Variations have
been made in the size of the PEG chains, the number of PEG chains conjugated to a
single Hb tetramer, the sites of PEGylation, the methods of conjugating PEG chains
to Hb, and the crosslink status of the Hb (Hu et al. 2007; Li et al. 2008; Li et al. 2009).
Acharya and coworkers found that when six PEG chains were conjugated to a single
Hb tetramer, the oxygen affinity of the Hb polymer increased in comparison to
native Hb (Li et al. 2007). It was previously proposed by Winslow and co-workers
(Rohlfs et al. 1998) that a total PEG mass around 50 kDa to one Hb molecule would
be sufficient to counteract vasoactivity of Hb in the bloodstream. Moreover, other
larger hemoglobin complexes, such as the zero-length crosslinked product by Bucci
and co-workers (Oxy Vita) (Matheson et al. 2002), are not vasoactive (Harrington

and Wollocko 2011; Martini et al. 2006; Palmer and Intaglietta 2014). From these
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studies one concludes that a way to counteract vasoactivity is to produce a polymer
with a large size or hydrodynamic volume (Palmer 2006; Palmer and Intaglietta
2014). A polymer of such a size can be produced by conjugating PEG onto the Hb
tetramer and will stay in the center of the blood flow preventing deleterious
endothelial NO scavenging (Alayash 2004; Palmer 2006; Palmer and Intaglietta
2014).
While most PEG chains have been attached to exposed Lys residues on the
Hb tetramer through NHS-Ester amidation, it is also possible to conjugate PEG
chains onto the Cys 93 residue (Li et al. 2008). This modification increased the
oxygen affinity of hemoglobin but allowed for oxygen deliver to ischemic tissues
(Abraham, Phillips, Kennedy 1983; Li et al. 2009). In addition, multiple PEG chains
generate a hydration shell around a single Hb tetramer in current PEGylated HBOCs,
increasing the hydrodynamic volume. In this chapter the reverse approach has been
utilized with a PEG polymer to which multiple Hb tetramers are attached by click
chemistry. Click chemistry is defined as a reaction that has a large thermodynamic
driving force that favors a single product. The click chemistry used to produce the
large Hb polymers is the thiol-maleimide reaction. A PEG backbone with eight arms,
each containing a terminal maleimide functional group (Mal-PEG), is capable of
reacting with Hb tetramers via the Cys 93 residues. Therefore, the maximum
number of Hb tetramers that may be conjugated to a single PEG backbone is eight.
However, it is more likely that once the Mal-PEG reacts with one Cys 93, it will then
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react with the other exposed Cys 93 in the same tetramer. Thus, one would expect
a lower maximum ratio of four, rather than eight, Hb bound to PEG if there is one
hundred percent reactivity. This method utilizes thiol-maleimide click chemistry to
produce a PEG Hb polymer distinguishable from all other PEG Hb products reported
thus far. As a large PEG backbone is covered by multiple proteins, the reverse of
traditional PEGylation schemes, we have called this method inside-out PEGylation.
Here we show that this form of PEGylation can create a PEG XL-Hb polymer via site
specific chemistry that has the potential to be a viable HBOC for highly hypoxic
tissues.
Materials
Untreated bovine blood was obtained from Animal Technologies (Tyler, TX).
Eight Arm Maleimide-PEG (Mal-PEG) was purchased from Creative PEGWorks
(Winston Salem, NC). Sephadex chromatography media were purchased from GE
Healthcare Biosciences (Pittsburg, PA). Micro separatory centrifuge filters (300
kDa) were purchased from Sartorius Stedim (Bohemia, NY). Hemox Antifoam and
the HEMOX oxygen analyzer were purchased from TCS Scientific (New Hope, PA).
DBSF was made by the method of Zaugg et al (Zaugg, King, Klotz 1975). All other
chemicals and gel filtration markers kit for protein molecular weights 29 kDa - 700
kDa were purchased from Sigma-Aldrich Co. (St. Louis, MO).

Methods
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Bis(3,5-dibromosalicyl) Fumarate (DBSF) Synthesis and Conformation
Bis(3,5-dibromosalicyl) fumarate (DBSF) was prepared by a procedure
similar to that for the succinate diester done by Walder et al. (Walder et al. 1979)
1.35 mL (0.0125 moles) of fumaryl chloride was mixed with 100 mL of benzene
(toluene can be substituted for benzene). Following that, 7.55 grams (0.0255 moles)
of 3,5-dibromosalicylic acid and 6.38 mL (0.05 moles or 6.06 g) of N,Ndimethylaniline were added to the previous mixture. The slurry was allowed to mix
at room temperature for three hours. After which, thirty mL of ice-cold deionized
water were added and the mixture was acidified with a few drops of 12 M HCl and
allowed to stir for another 20 minutes. The liquid was decanted off, and the solid
was washed three times with benzene/toluene via vacuum filtration. The sample
was then allowed to dry and it was scraped into a beaker in which just enough
acetone was added to dissolve the DBSF (the solution became clear not cloudy) and
an equal amount of water was added. If the DBSF came out of solution slightly, more
acetone was added to make the mixture clear. The sample was then put through a
vacuum filtration system to remove any solid particles that did not dissolve in the
acetone/water and the liquid was collected. Following this, 6 M HCl was added to
the mixture until the DBSF was seen to precipitate out of solution, and turned
cloudy again. If the pH was lowered, and the DBSF did not come out of solution,
water was added to help the DBSF precipitate out. Figure five shows the scheme by
which DBSF was synthesized. The mixture was once again run though the filtration

system, and the solid DBSF was collected. The product, C18H8O8Br4•C2H6O, had a
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melting point of 223-225oC.
Around seven mg of the produced DBSF, Sigma Aldrich’s DBSF, and LKT
Laboratories DBSF were taken and separately suspended in deuterated acetone
(Acetone-d6). NMR spectra were taken of each sample on a Gemini-300. The solvent
was not ideal to produce a reliable NMR spectrum, so the procedure was repeated
the same as before but deuterated acetone was substituted for deuterated DMSO
(DMSO-d6).
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Figure 5. Synthesis of DBSF.

Crosslinked Hemoglobin Synthesis
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Methods described by Hanash and Shapiro (Hanash and Shapiro 1981) and
Dozy et al. (Dozy, Kleihauer, Huisman 1968) were modified for the purification of
Hb from bovine blood. After ammonium sulfate fractionation and dialysis, the
impure Hb solution was added to Sephadex A-50 gel in 50 mM Tris, 1 mM NaCN, pH
8.5 buffer in centrifuge tubes. Unbound proteins were separated by centrifugation
and then the bound Hb was released from the gel upon the addition of Tris buffer at
pH 7.2. The procedure for crosslinking oxy-hemoglobin was carried out as outlined
by Walder et al. (Walder et al. 1979). DBSF was reacted with oxy-hemoglobin at a
molar ratio of 1 Hb: 1.2 DBSF at room temperature for four hours before dialysis in
50 mM Tris, 1 mM NaCN pH 8.5 buffer. Separation of unmodified Hb from βXL-Hb
was accomplished by a pH gradient of 8.5 to 6.8 on a Kontes Chromaflex column
using Sephadex A-50 gel in 50 mM Tris, 1 mM NaCN buffer. SDS-PAGE procedures,
outlined by Schmidt et al. (Schmidt and Brosious 1979), showed equal intensity
bands at 14.4 kDa and 30 kDa, verifying crosslinking.
Reduction of Methemoglobin to Oxyhemoglobin
The procedure used was a revised version of the Dixon and McIntosh method
(Dixon and McIntosh 1967). A 25 cm x 1 cm Kontes column was loaded with
Sephadex G-25 gel in 5 mM phosphate buffered saline solution (PBS) pH 7.0, 1 mM
EDTA buffer. Following equilibration, 0.5 mL of a 0.1 g/mL solution of sodium
dithionite was added to the column followed by addition of 0.3 mL of the PBS buffer.
A 5 mL sample was then passed through the gel and reduced by the dithionite.

PEGylation of Crosslinked Hemoglobin
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XL-Hb was dialyzed in 50 mM MOPS, 10 mM EDTA, pH 7.4 buffer. The
sample was then passed through a 0.2 micron filter to remove any particulates. XLHb was then reacted with a 40 kDa, 8-Arm Mal-PEG at a molar ratio 80 XL-Hb: 1
Mal-PEG at room temperature for one week. Unreacted Hb was removed using a
300 kDa micro separatory centrifuge filter spun at 2950 g. The retained complex
was collected for further purification.
Purification of PEGylated Crosslinked Hemoglobin via Size Exclusion Chromatography
A pre-packed Sephacryl S-300 column was equilibrated with 50 mM MOPS,
0.15 M NaCl, pH 7.4 buffer. Concentrated samples retained by the 300 kDa filter
were then applied, and the large molecular weight PEG XL-Hb fractions were
collected and concentrated. The concentrated samples were then ran on a prepacked Sephacryl S-500 column that was previously equilibrated with 50 mM
MOPS, .15 M NaCl, pH 7.4 buffer. Known protein standards were ran to determine a
standard curve.
SDS-PAGE of PEGylated Hemoglobin
Confirmation of large molecular weight species produced by PEGylation of
XL-Hb was obtained using a PhastGel SDS-PAGE system (Schmidt and Brosious
1979).
Determination of Molecular Weight via Analytical Ultracentrifugation (AUC)
AUC was carried out in a Beckman Coulter ProteomeLab XL-A analytical
ultracentrifuge using standard 2 sector cells with quartz windows in 4- or 8-hole

rotors. All sedimentation velocity experiments were at 50,000 rpm with a preset
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scan number of 100 per cell. The reference sector was filled with 450 µL of buffer
(50 mM MOPS, 10 mM EDTA, pH 7.4) and the sample sector was filled with 430 µL
of sample with an absorbance at 412 nm (1 cm path length) between 0.75 and 1.1.
Buffer density (1.00718 g/mL) was measured at 20.0 C in a Mettler/Paar
Calculating Density Meter DMA 55A and the buffer viscosity (0.010543 Poise) was
measured in an Anton Parr AMVn Automated Microviscometer. A partial specific
volume of 0.746 mL/g for bovine hemoglobin was used in calculating molecular
weight (DeMoll et al. 2007). Data were analyzed using the program Sedfit
(www.sedfit.com). Molecular weights and sedimentation coefficients were
determined using the continuous c(s) mode in the sedfit program. Native tetrameric
hemoglobin yielded an s20,w value of 4.25S which agrees with the accepted value
(Field and O'Brien 1955). The c(s) plots were deconvoluted using nonlinear leastsquares fitting algorithms available in the Origin (v. 9.0) software package
(OriginLab Corporation, Northapmton, MA). Data were fit to multiple Gaussian
components, increasing the number of components until residual plots (data-fit)
were random and the chi square value for the fit was minimal. Six components were
needed to adequately describe the c(s) distribution.
Secondary Structure Characterization of PEG XL-Hb via Circular Dichroism
CD spectra were obtained on an OLIS DSM 20 CD Spectrophotometer. Water
was used to collect baseline data and as the dilution solvent for the Hb samples. The
final Hb concentrations in the cuvette for the three samples were 0.01420 mg/mL

PEG XL-Hb, 0.02301 mg/mL Hb, and 0.02238 mg/mL XL-Hb. For each sample a
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wavelength range from 190-260 nm was scanned. The spectra were smoothed using
Solvitsky Golay 7 point method (Whitmore and Wallace 2004; Whitmore and
Wallace 2008).
Thermal Denaturation Procedure
Experiments followed the procedure according to Olsen (Olsen 1994).
Experiments were conducted in 10 mM MOPS, 0.9 M guanidine HCl pH 7.0. Samples
were prepared so that the absorbance at 409 nm was between 1 and 1.2. Samples
were monitored every minute on an Agilent 8453 spectrophotometer. A
temperature increase of 0.3C/ min was controlled by Neslab Endocal, Temperature
Programmer ETP-3, and Digital Controller/Readout DCR-4. Absorbance versus
temperature was plotted and the fraction denatured was determined by the
equation FD = (A-AN) / (AD-AN) where A is experimental absorbance, AN is
absorbance of native protein, and AD is absorbance of denatured protein. AN and AD
were determined by fitting a linear line to the portion of the absorbance versus
temperature plot that corresponded to the effect of temperature on the native or
denatured spectrum respectively. The curve of FD versus temperature was
smoothed in Microsoft Excel with an exponential smoothing function.
Autoxidation Experiments
Autoxidation of native, crosslinked, and PEG crosslinked hemoglobin was
carried out according to Yang and Olsen (Yang and Olsen 1989). Hemoglobin
samples were fully reduced and dialyzed in 10 mM MOPS, pH 7.0. Sodium cyanide
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was added to each sample and allowed to equilibrate at room temperature for five
minutes prior to data collection. The experiments were conducted at 37C and
allowed to equilibrate before spectra were recorded from 500-700 nm on an Agilent
8453 spectrophotometer.
Oxygen Binding Studies For Determination of P50 and Hill Coefficients
The samples, fully reduced with dithionite, were added to 4.0 mL of 10 mM
MOPS, pH 7.4 and 10 L of Hemox Antifoam. Oxygen binding was determined using
a HEMOX Analyzer for native bovine Hb, native Hb with inositol hexaphosphate
(IHP), XL-Hb, XL-Hb with IHP, and PEG XL-Hb. Hill coefficients (n) and oxygen
affinity (P50) were obtained from Hill plots.
Results
Bis(3,5-dibromosalicyl) Fumarate (DBSF) Synthesis and Conformation
As seen in Figures 6-8 (self-synthesized, Sigma, and LKT Laboratories DBSF)
via the NMR spectra that there are three noteworthy peaks between 7.2 ppm and
8.6 ppm. The integration of these peaks in each of the H-NMR were calculated to be
δ 8.35(2Hd, J=2.1 Hz), 8.10(2Hd, J=2.1 Hz), 7.35(2Hs), δ 8.35(2Hd, J=2.4 Hz),
8.10(2Hd, J=2.4 Hz), 7.35(2Hs), and δ 8.35(2Hd, J=2.7 Hz), 8.10(2Hd, J=2.4 Hz),
7.35(2Hs) for self-synthesized, Sigma, and LKT Laboratories DBSF respectively. The
two peaks between 8.0-8.4 ppm corresponds to the aromatic hydrogens, while peak
at 7.35 corresponds to the aliphatic hydrogens. This verified a successful DBSF
synthesis in relation to Sigma and LKT Laboratories purchased DBSF by the nearly
identical H-NMR spectra.
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Figure 6. Self-synthesized DBSF H-NMR spectrum in DMSO-d6 solvent with an expanded spectrum above showcasing the range 7.2 ppm to 8.6 ppm. The peaks of
interest and their integration can be seen at δ 8.35(2Hd, J=2.1 Hz), 8.10(2Hd, J=2.1
Hz), 7.35(2Hs).
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Figure 7. Sigma purchased DBSF H-NMR spectrum in DMSO-d6 solvent with an expanded spectrum above showcasing the range 7.2 ppm to 8.6 ppm. The peaks of
interest and their integration can be seen at δ 8.35(2Hd, J=2.4 Hz), 8.10(2Hd, J=2.4
Hz), 7.35(2Hs).
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Figure 8. LKT Laboratories purchased DBSF H-NMR spectrum in DMSO-d6 solvent
with an expanded spectrum above showcasing the range 7.2 ppm to 8.6 ppm. The
peaks of interest and their integration can be seen at δ 8.35(2Hd, J=2.7 Hz),
8.10(2Hd, J=2.4 Hz), 7.35(2Hs).

XL-Hb Reaction Verification
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Figure nine depicts the crosslinked Hb tetramer under oxy-conditions in
which the fumarate from the DBSF molecule links the Lys821 and Lys822. This
oxyhemoglobin crosslinking occurs on the -subunit end of the central cavity in the
Hb tetramer. Because it stabilizes the R state of Hb, the XL-Hb already shows a
higher affinity for oxygen than standard Hb within a RBC or even uncrosslinked Hb.
Verification of this XL-Hb product was seen via SDS (Figure 10) with distinct bands
around both 14.4 kDa and 30.0 kDa, ideally of equal intensity. Each Hb monomer is
around 15 kDa, so the band at 14.4 kDa is representative of the alpha subunits
disociation, where the band around 30.0 kDa indicates that the beta subunits were
in fact linked together.
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Figure 9. Model of oxy-XL Hb. DBSF crosslinks within the central cavity at the 2,3BPG binding site.
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Figure 10. SDS confirmation of the crosslinked Hb Product. Lanes 1 and 4 are the
markers while 2, 3, 5, and 6 are samples of XL Hb. The band at 14.4 kDa is a result
from the alpha subunit separation from the Hb tetramer, while the band around
30.0 kDa is a result of the XL beta subunits.

XL-Hb Purification Verification
The separation of uncrosslinked Hb, XL-Hb, overly crosslinked Hb and
MetHb by Sephadex A-50 gel is possible due to the removal of two positive charged
residues (Lys821 and Lys822) on the overall protein. This means that the less
positive XL-Hb will bind to the gel more tightly then the more positive
uncrosslinked Hb. As the pH of the buffer is lowered, the various Hb species will
gain positive charges and will be released from the gel. The species of Hb elute from
the column in the order: native Hb, Xl-Hb, overly Xl-Hb, and finally (with a drastic
pH drop) MetHb. Overly XL-Hb will be more negative as other Lys groups (besides
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the desired Lys821 and Lys822) have reacted with DBSF. Figure eleven shows the
absorbance at 415 nm via UV-Vis in relation to the fraction number coming off the
column. By looking at the data in Figure 11, it is evident that there were at least
three major peaks as expected. The fractions were pooled together for each peak
and SDS was run to determine which pools contained the purest samples of XL-Hb.
Figure 12 shows two SDS gels side-by-side that represents the eight pools. Figure
12, reading left to right, lanes 3, 5, 10, and 12 are markers while the left most lane
(1) is the pool collected from the fractions that were last to come off the column and
lane eleven is the pool collected from the beginning fractions. It can be seen reading
left to right that the 30.0 kDa band becomes fainter until it disappears in the sample
in lanes nine and eleven. This agrees with the fact that uncrosslinked Hb elutes off
the column first, followed by XL-Hb as is seen by the darkening presence of the 30.0
kDa band indicating Lys821 Lys822 crosslinking.
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Figure 11. Graph of UV-Vis Spec Samples from Ion Exchange Column Fractions. The
wavelength at 415 nm was used because at this wavelength the absorbance is
specific for the heme group within the Hb. Wavelengths at 542 nm, and 578 nm are
also for the heme groups but were not used to generate the chromatogram. It is
apparent that there are 3 distinct peaks which correlate to un-crosslinked Hb, XLHb, and finally overly XL-Hb.
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Figure 12. SDS from Ion Exchange Column Pulls. Lanes 3, 5, 10, 12 are the marker
while the other lanes are from the 8 pulls created from the fractions shown in figure
11. Reading from right to left, the pulls correlate from early fractions that were
collected to the last fractions collected. As seen in lanes 9 and 11 there is only a band
present at 14.4 kDa correlating to complete Hb dissociation of the four monomers.
Continuing reading right to left the band at 30.0 kDa becomes increasingly darker
correlating to a higher production of XL-Hb.

Crosslinked Hemoglobin (XL-Hb) Production and Confirmation of PEGylation at
Cysteine 93 Residue
Verification of XL-Hb product was obtained with SDS-PAGE (Figure 13) that
showed distinct bands of equal intensity around 14.4 kDa and 30.0 kDa. An absence
of the 30.0 kDa band with the concomitant presence of a new band at the origin of
the gel (Figure 13, lane 3) was present in the PEGylated Hb sample.
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Figure 13. SDS Verification of PEG XL-Hb. Lanes 2 and 4 are the marker proteins,
while Lane 1 is XL-Hb and Lane 3 the PEG XL-Hb sample.

Conformation of Large Molecular Weight Species and Purification of PEG XL-Hb from
Unreacted XL-Hb
Preliminary purification was accomplished by use of a 300 kDa filter, where
XL-Hb passed through the filter while the PEG XL-Hb compound was retained.
The PEGylated sample was further purified with an S-300 column (Figure 14) and
the large molecular weight species were then applied to an S-500 column for

additional purification and characterization. It was evident from size exclusion
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chromatography (SEC) that PEG XL-Hb and unreacted XL-Hb Hb can be
successfully separated with this two phase SEC protocol. On the S-500 column the
characteristic elution peak around 250 mL was XL-Hb, while the elution peak
around 220 mL was the large PEG XL-Hb sample (Figure 15).

Figure 14. Normalized PEG XL-Hb SEC chromatogram from the S-300 column.
Unreacted XL-Hb eluted around 80 mL while the larger PEG XL-Hb product eluted
between 40 and 65 mL. All four samples were prepared in the same method on
different days.
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Figure 15. A normalized chromatogram from the S-500 column of a PEG XL-Hb
(Red) sample post S-300 SEC and an un-PEGylated XL-Hb sample (Blue). Unreacted
XL-Hb elutes around 250 mL while the larger PEG XL-Hb product elutes around
220 mL.

Size Determination of PEG XL-Hb Samples via Analytical Ultracentrifugation
Figure 16A shows the Analytical Ultracentrifugation (AUC) sedimentation
velocity analysis of the PEG XL-Hb purified with a S-300 column and subsequently
by S-500 column (see Figure 15). Sample heterogeneity was observed by monitoring
the amount of product in relation to sedimentation coefficients. Native Hb has a s20,w
of 4.25S (Field and O'Brien 1955) indicating that larger species are PEGylated
samples. Most (60%) of the species lie in the sample range from 3 Hb : 1 PEG to 8

Hb : 1 PEG. The sample was heterogeneous in composition but there was a
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consistent pattern of heterogeneity between different samples. Figure 16B shows a
deconvolution of a c(s) versus s20,w indicating the predominant HBOC species as 3
Hb : 1 PEG.

Figure 16. (A) c(s) versus s20,w plot of four different PEG XL-Hb samples determined by AUC.
Approximately 60% of the product’s composition ranges from 4.5 S to 10S, indicating three to
eight Hb tetramers conjugated onto a single PEG backbone. (B) A deconvoluted c(s) versus s20,w of
a sample from Figure 16A showing the major speciation within the PEGylated sample.
48

Circular Dichroism Analysis of Secondary Structure in PEG XL-Hb
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Circular Dichroism (CD) was used to determine if crosslinking and
PEGylation perturbed the secondary structure of Hb. Spectra of native Hb, XL-Hb,
and PEG XL-Hb showed the characteristic signals for alpha helical structure at 195,
208, and 222 nm (Figure 17). Hemoglobin is 75% alpha helical by nature.

Figure 17. CD spectra of native Hb (green), XL-Hb (blue), and PEG XL-Hb (red).
All three spectra show the characteristic signals for alpha helical structure at 195
nm, 208 nm, and 222 nm.

Thermal Denaturation of Hb Samples
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Thermal denaturation curves for native Hb, XL-Hb, and PEG XL-Hb (Figure
18) showed that crosslinking and PEGylation increase the stability of the Hb
tetramer compared to native Hb (Figure 18). The melting temperatures (Tm) for the
samples can be seen in Table 4. A single factor ANOVA showed that the differences
between all the Tm values are statistically significant.

Figure 18. Comparison of native Hb (Blue), XL-Hb (Red), and PEG XL-Hb
(Green) fraction denatured versus temperature based on the absorbance at
409 nm.
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Autoxidation of Hb Samples
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Autoxidation experiments were conducted at 37C to see the effects of
crosslinking and PEGylation on the autoxidation rates at physiological
temperatures. Table 4 contains the relative rate constants (krel) of autoxidation. The
relative rate constants were determined by dividing the slopes of methemoglobin
production for XL-Hb and PEG XL-Hb by the slope of native Hb. It was determined
that crosslinking increased Hb autoxidation rate by 1.59 times and PEGylation
further increased the autoxidative rate to 3.43 times that of native Hb. Figure 19
shows the spectral changes observed in the PEGylated Hb sample. There was a
decrease in the oxyhemoglobin absorbance at 540 and 576 nm as the sample
autoxidized.
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Figure 19. Autoxidation and spectral changes in PEG XL-Hb sample. The spectra
showed a decrease in absorbance at 576 and 540 nm and an increase of absorbance
at 630 and 510 nm as the sample was allowed to oxidize.
Oxygen Binding Determination of Hb Samples
Figure 20 shows the experimental determined oxygen binding curves. Table
4 shows the calculated P50 and Hill coefficients (n) determined for native Hb, XLHb, and PEG XL-Hb. The XL-Hb species had a higher oxygen affinity than native,
stroma-free hemoglobin as expected (Walder et al. 1979). The addition of Inositol
Hexaphosphate (IHP) to native Hb shifted the oxygen binding curve to the right but
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addition of IHP to XL-Hb and PEG XL-Hb did not show this shift. The PEG XL-Hb
sample had a similar oxygen affinity to XL-Hb. The Hill coefficients showed that the
cooperativity of Hb decreased (from 2.91 to 1.72) once Hb was crosslinked
(stabilizing the R state) and decreased slightly more following PEGylation (1.72 to
1.43).

Figure 20. Comparison of native Hb (Blue), XL-Hb (Green), and PEG XL-Hb
(Red) oxygen binding curves.
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Table 4. Experimentally determined Tm (C) from fraction denatured curves, relative
rates of autoxidation at 37C, and P50 (torr) and Hill Coefficients determined at 37C
for native bovine Hb, XL-Hb, and PEG XL-Hb.
Sample

Tm (°C)*

krel

P50 (torr)

Hill Coefficient (n)

Native Hb

41.3 ± .9

1

11.25 ± .17

2.91 ± .06

XL-Hb

54.1 ± .5

1.59 ± .15

9.16 ± .84

1.72 ± .06

PEG XL-Hb

48.9 ± 1.5

3.43 ± .53

9.67 ± .39

1.43 ± .06

*ANOVA F=80.0, Fcrit=3.5

Discussion
An inside-out PEG XL-Hb polymer was successfully produced by reacting
the Cys 93 residue of the Hb tetramer with an 8-armed PEG. The SDS-PAGE of XLHb (Fig. 13) showed a band at 30.0 kDa indicative of the β subunits covalently linked
together by bis-(3,5-dibromosalicyl)fumarate (DBSF) under oxy-conditions while
the band at 14.4 kDa was due to the α monomers. The PEGylated product showed
the absence of the 30.0 kDa band, specific for the XL subunits, and the presence of a
new band at the origin suggesting successful PEGylation. The conserved presence of
the  subunit band at 14.4 kDa in the PEG XL-Hb sample indicates a lack of
PEGylation on these subunits. The Cys 93 residue is the only cysteine available in
bovine Hb for thiol-maleimide click chemistry. Unlike human Hb, bovine Hb has only
one Cys residue on each  chain for thiol-maleimide specific click chemistry; there
are no Cys residues on the  chains of bovine Hb.

It has been found that increasing the Hb polymer size is one way to
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counteract vasoactivity (Harrington and Wollocko 2011; Martini et al. 2006;
Matheson et al. 2002; Palmer 2006; Palmer and Intaglietta 2014). A larger polymer
will move in the center of the blood flow preventing NO scavenging from endothelial
tissue (Palmer 2006; Palmer and Intaglietta 2014). Inside-out PEGylation was used
to produce a Hb nanoparticle. Polymer size determination and characterization
were accomplished by gel filtration and AUC. It was found that the samples were
heterogeneous, but reproducible in their pattern of heterogeneity (Figure 16A). The
polymeric species could not be resolved with S-500 size exclusion chromatography
(Figure 15). The calculated apparent molecular weight of the sample was around
500 kDa based on the standard curve from protein standards. However, the elution
volume was nearly identical to that of the apoferritin standard (443 kDa). While
these results would indicate a complex of 7 Hb : 1 PEG, the apparent molecular
weight determined by this technique does not represent the actual polymer mass
due to the large hydrodynamic volume of the PEG. Previous PEGylated HBOCs have
been shown to have a large increase in their volume and hydrodynamic radius. The
volume can increase over ten times what it was originally while the hydrodynamic
radius can more than double when compared to that of native hemoglobin (Hu et al.
2007; Li et al. 2008; Meng et al. 2014; Wang et al. 2014). In addition, appropriate
standards for the PEGylated samples are not available. As a result, PEGylation would
be expected to yield a larger apparent molecular weight by SEC when compared to
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traditional protein standards as seen in the product. It is speculated, however, that
the data indicates how the polymer size would appear in vivo.
Although Hb is in high molar excess for the reaction, an 8 Hb : 1 PEG is not
the major polymer species, as shown by the AUC results (Figure 16). After the
reaction of a tetramer to one arm of the PEG the probability of an unreacted arm
reacting with the other exposed thiol of the same Hb is greatly increased. As seen in
figure 16A, 60% of the polymer species possess three to eight Hb tetramers
conjugated onto one Mal-PEG backbone. The deconvolution data (Fig. 16B) indicates
that there are four predominant PEG XL-Hb species being produced. Three of the
four species have three to six Hb tetramers conjugated to one Mal-PEG. The peak
near 2.5S is unconjugated hemoglobin. The data indicates the major product is 3
Hb : 1 PEG complex, shown diagrammatically in Figure 21. The broadening of the
major peak in Figure 16B shows the difficulty in separating the 3 Hb and 4 Hb
species. Maleimide-derived click chemistry shows a high specificity for thiol groups
but is not restricted to these reactions. Maleimide reactions with Lys residues are
much less favorable at pH 7.4 than to Cys residues, yet plausible (Dondoni 2008;
Hoyle and Bowman 2010; Khan 1985).
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Figure 21. Schematic representation of Inside-out PEGylated crosslinked
hemoglobin. While possible to conjugate eight Hb tetramers to one PEG polymer, it
is more probable two arms will bind to a single tetramer. The major species
produced is depicted above (3 Hb : 1 PEG).

The large size of a 3 Hb: 1 PEG species will likely prevent the HBOC from
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coming into close proximity with the arterial lining, thus preventing NO scavenging
in vivo (Palmer 2006; Palmer and Intaglietta 2014). As observed for PEGylated
HBOCs of comparable size, the size of inside-out PEGylated Hb should be sufficient
to eliminate vasoconstrictive side effects (Bjorkholm et al. 2005; Li et al. 2007;
Vandegriff et al. 2003). The increased volume of the PEG XL-Hb complex will also
hinder filtration of the polymer by the kidneys, increasing circulation time in vivo
(Conover et al. 1997; Vandegriff et al. 2003). Crosslinking of the tetramer prevents
its dissociation, reducing concerns of nephrotoxicity. These modifications increase
the stability of the Hb tetramer as seen in the fraction denatured results when
compared to native Hb (Table 4). Thermal denaturation experiments (Figure 18)
showed that crosslinking greatly increases the stability of the tetramer compared to
that of native Hb (Native Hb = 41.3C, XL-Hb = 54.1C) (White and Olsen 1987).
PEGylation lowers the stability of the tetramer (48.9C) compared to the XL-Hb
species but the PEGylate species is still more stable than native Hb. This indicates
that crosslinking dictates the tetramer stability more than inside-out PEGylation.
While crosslinking and inside-out PEGylation increase the stability of the
tetramer, it also increases the autoxidation rate of Hb. It has been previously shown
that crosslinking under oxy-conditions with DBSF increases the rate of oxidation
(Yang and Olsen 1989). The data presented here agrees with previously reported
krel values and spectral changes affiliated with autoxidation of the heme (see Figure
19 and Table 4). Upon PEGylation, the rate of oxidation increases significantly to

3.43 times that of native Hb. Previous work has shown that PEGylation of Hb
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increases the rate of autoxidation. Acharya and coworkers showed that PEGylated
Hbs exhibit a 2-3 fold increase in oxidation rates (regardless of the methodology
used for PEGylation) when compared to native Hb (Hu et al. 2008). It is also known
that conjugation of PEG onto Cys 93 shows a faster rate of oxidation when
compared to PEGylated Hb species that are modified on Lys residues (Hu et al.
2008; Wang et al. 2014). Cys 93 is adjacent to the proximal His that coordinates
with the iron in the heme. PEGylation on this residue perturbs the heme
environment allowing a larger number of water molecules to enter and facilitate
oxidation. In addition, PEGs also have the unique property to sequester
approximately 2-3 water molecules per repeating unit (Hu et al. 2005), increasing
the odds for water-mediated oxidation. However, it has been speculated that the
rate of autoxidation will be less in vivo due to antioxidant and reducing agents
present within plasma (Hu et al. 2008; Snyder et al. 1987; Yang and Olsen 1989).
Addition of IHP with no observable shift in oxygen affinity for XL-Hb
verified the success of the oxy-crosslinking procedure between the 82 Lys residues
that blocks the allosteric binding site (Walder, Walder, Arnone 1980). The Cys 93
residues are exposed only within the R state tetramer, and conjugation to this site
produces a higher oxygen affinity Hb (Abraham, Phillips, Kennedy 1983). Previous
studies also demonstrated that an increased oxygen affinity was a byproduct of
PEGylation, independent of the conjugation site (Li et al. 2009). The data presented
here show that the conjugation of PEG to Cys 93 does not further increase the

oxygen affinity if the Hb is previously crosslinked in a high oxygen affinity state,
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unlike other PEGylated HBOCs (Table 1). XL-Hb stabilizes the R state conformation
of the tetramer, increasing oxygen affinity in comparison to stroma-free Hb.
Negligible changes were found between P50 values for XL-Hb (9.16 torr) and PEG
XL-Hb (9.67 torr). Other PEG-based HBOCs have exhibited large increases in
oxygen affinity post crosslinking and PEGylation (P50 from 3-6 Torr) (Hu et al. 2007;
Li et al. 2008; Li et al. 2009; Lui, Dong, Kluger 2008; Lui et al. 2012). Crosslinking
and inside-out PEGylation dramatically decrease the cooperativity of the Hb
tetramer (Table 4). There were negligible differences between the three samples CD
spectra indicating that crosslinking and PEGylating hemoglobin do not significantly
change the secondary structure of the protein (Figure 17) (Sreerama, Venyaminov,
Woody 2000; Whitmore and Wallace 2004; Whitmore and Wallace 2008). Thus, the
loss of cooperativity is not a result of secondary structure conformational changes,
but rather from chemical modifications. Crosslinking of the tetramer restricts the
movement needed for cooperativity, while PEGylation may further restrict
quaternary structural change. The heightened oxygen affinity ensures that the
polymers will be fully oxygenated leaving the lungs and will only deliver it to the
most oxygen deficient tissues. This in turn will help prevent tissue necrosis in
patients who have lost severe amounts of blood.
The inside-out PEG βXLHb presented here represents both a poly Hb and a
dendrimeric structure. Several other poly or dendrimeric hemoglobins have been
produced by both genetic and chemical means. Genetically, placements of Cys

mutants at specific positions have led to the production of polymeric dimers,
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trimers, and octamers of Hb tetramers (Bobofchak et al. 2003; Fablet et al. 2003;
Faggiano et al. 2011; Fronticelli et al. 2001; Vasseur-Godbillon et al. 2006). The
largest of these was ~500KDa in mass and had a diminished pressor compared to
cross-linked tetrameric Hb, presumably due to a decreased extravasation
(Bobofchak et al. 2003). Thus, the same result is expected for the PEGβHb reported
here. Kluger and Zhang (Kluger and Zhang 2003) have reported the synthesis of a
Hb dendrimer made by attaching β cross-linked Hb to generation 4.0
polyamidoamine dendrimer (PAMAM). As expected the product had very high
oxygen affinity. Kluger and co-workers (Singh et al. 2015b) also produced bistetrameric Hb using double cross-linking and click chemistry. The advantage of
these approaches is the specificity of the connections between the Hb tetramers
making the polyHb, but the disadvantage is the amount of genetic manipulation or
chemical synthesis needed to produce such products. Inside-out PEGylation offers
the possibility of making similar sized polyHbs with commercially available
reagents. In addition, the methods presented here should be easily applicable to
many other proteins.
Conclusions
We have successful produced an inside-out PEGylated XL-Hb complex.
Inside-out PEGylation has been shown to maintain secondary structure, increase
protein stability, without altering the P50 value compared to the native protein.
Unlike previous PEGylated HBOCs, inside-out PEGylation does not dictate protein

function, specifically the oxygen affinity. The functional properties of the polymer
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are controlled by the method under which Hb was crosslinked. This form of protein
modification has applications in many areas of biochemistry beyond HBOC
development, such as PEGylation of drug delivery agents and applications with
other protein therapeutics. In the past there have been a few dendrimeric Hb
particles produced (Fablet et al. 2003; Fronticelli et al. 2001; Kluger and Zhang
2003). However, none of these have utilized multi-arm PEGs in their production.
Until now multi-arm PEGs have primarily been utilized in the creation of hydrogels
and biofilms (Guebeli et al. 2012; Meyerbroeker, Kriesche, Zharnikov 2013). The
results reported here introduce applications of multi-arm inside-out PEGylation that
can be used in protein chemistry and enzymology. Applications of inside-out
PEGylation could be expanded to the production of multi-enzyme complexes. Insideout PEGylation may be efficacious in biomacromolecular production and in
bioconjugate chemistry.

CHAPTER IV
“INSIDE-OUT” PEGYLATION OF BOVINE -CROSSLINKED HB VIA STRAIN
PROMOTED AZIDE-ALKYNE CYCLOADDITION
Chapter Introduction
A viable alternative to current blood transfusions has been actively pursued
for several decades with varying degrees of success. A limited supply of blood,
dependent on human donors, has necessitated the creation of a hemoglobin-based
oxygen carrier (HBOC) derived from non-human sources. Such a product would be
responsible for carrying oxygen to hypoxic tissues and might be useful as a response
to hemorrhagic trauma. However, a HBOC has a utility that exceeds applications in
hemorrhagic shock. It may also be used to treat carbon monoxide poisoning, acute
anemia, organ ischemia, and cardioplegia—all of which induce oxygen deprivation
(Jahr, Akha, Holtby 2012). The value of such a product would be augmented if it
could be minimally refrigerated, non-immunogenic, universal for all blood types,
and available at a minimal cost whilst possessing a long shelf life (Estep et al. 2008;
Ness and Cushing 2007; Reid 2003; Sakai et al. 2000). All hemoglobin-based oxygen
carriers must begin with source of hemoglobin. However, application of stroma-free
unmodified hemoglobin (Hb) to a living system results in complications. The Hb
tetramer dissociates into two  dimers whose small size enables
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them to pass into the kidneys where nephrotoxicity is observed. The short
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circulation time associated with an unmodified Hb tetramer does not mitigate the
impact of another harmful effect—vasoconstriction induced by the scavenging of
nitric oxide, a natural vasodilator found in the endothelial walls (Doherty et al.
1998; Muldoon et al. 1996; Reid 2003). The avoidance of vasoconstriction and
tetramer dissociation while maintaining the ability to deliver oxygen efficiently has
become the basis of all HBOC development.
Crosslinking of extracted hemoglobin via the alpha subunits is one approach
at preventing tetramer dissociation in vivo. This may be accomplished by the use of
a crosslinking reagent, such as bis-(3,5-dibromosalicyl)fumarate (DBSF), under
deoxy- conditions (Tye et al. 1983; Zaugg, King, Klotz 1975). Crosslinking of the Hb
tetramer under oxy- conditions using this same reagent likewise prevents
dissociation of the tetramer. However, these two modifications have opposite effects
on the affinity with which the HBOC binds oxygen (White and Olsen 1987; Yang and
Olsen 1991). HBOC polymer production methodologies have ranged from
dentrimeric Hb, liposomal encapsulated Hb, bis-tetrameric Hb, and PEGylated Hb
particle creation (Agashe and Awasthi 2009; Bradley et al. 2002; Fablet et al. 2003;
Fronticelli et al. 2001; Kluger and Zhang 2003; Lui et al. 2012; Xiong et al. 2012).
Production of a HBOC with a large molecular weight—by polymerization of Hb or
conjugation of Hb to a polyethylene glycol (PEG) backbone—has been shown to
attenuate vasoconstriction as seen with Hemospan produced by Winslow and
colleagues (Bjorkholm et al. 2005; Vandegriff et al. 2003; Vandegriff and Winslow

2009). It has been found that a large polymer that cannot get close enough to the
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endothelial lining, thus preventing harmful NO scavenging (Martini et al. 2006;
Palmer 2006; Palmer and Intaglietta 2014). Furthermore, polymers of large
molecular weight, such as the Oxy Vita product developed by Bucci and colleagues
(Matheson et al. 2002), have been shown non-vasoactive in vivo (Harrington and
Wollocko 2011; Matheson et al. 2002). One method to generate a polymer with a
large molecular volume is through PEGylation. PEG has been shown to sequester
two to three water molecules per repeating unit, which can dramatically increase
the hydrodynamic volume and polymer radius (Alayash 2004; Hu et al. 2005).
General PEGylation of proteins has also increased the therapeutic value of the
product by masking the protein from the immune system and preventing filtration
through the kidneys (Bailon and Berthold 1998; Harris and Chess 2003; Roberts,
Bentley, Harris 2002). Varying the size of the PEG chains, the number of chains
conjugated to a protein, and the sites and methods of conjugation of PEG to Hb
modulate the effects of PEGylation of a protein to different degrees (Hu et al. 2007;
Li et al. 2008; Li et al. 2009). For example, conjugation of six PEG chains to a single
Hb tetramer increases the oxygen affinity (Li et al. 2007). It has also been
hypothesized that conjugation of Hb to a PEG mass greater than 50 kDa may
counteract the vasoactivity of stroma free Hb in vivo (Rohlfs et al. 1998).
This paper offers a modification of the unique scheme of “inside-out”
PEGylation presented previously in Chapter 3 of this dissertation. The basic

68
stratagem of conjugating several bovine cross-linked Hb tetramers to a single eightarm 40 kDa PEG backbone remains unchanged. However, the PEG is conjugated to
the Lysine residues of both the alpha and beta subunits of the tetramer. Such a
conjugation necessitates two steps. Firstly, the Lysine -amino groups must be
activated by reaction with dibenzocyclooctyne-N-hydroxysuccinimidyl ester (DIBONHS) via an NHS-ester mediated amidation. The alkyne of the subsequent product is
then reacted with the azide group conjugated to one arm of the PEG backbone (N3PEG). In the past, copper (Cu+) mediated azide-alkyne cycloaddition (CuAAC) has
been previously utilized to produce a bis-tetrameric hemoglobin oxygen carrier
(Foot, Lui, Kluger 2009; Singh et al. 2015a; Wang and Kluger 2014; Yang and Kluger
2010). These previous CuAAC have been efficacious in Hb polymer creation.
However, the reaction presented here is not done via traditional copper mediated
azide-alkyne click chemistry but rather by strain promotion found within the alkyne
(Campbell-Verduyn et al. 2011; Gold et al. 2012). This removes any possible
contamination of the final product by copper, which may have adverse medical
effects (Campbell-Verduyn et al. 2011; Gold et al. 2012). Figure 22A shows the
activation of a Lys on Hb, while Figure 22B shows the strain promoted azide-alkyne
cycloaddition to achieve inside-out PEGylation. We believe this product will be a
successful HBOC candidate to deliver oxygen nondiscriminatory to tissue rather
than just to hypoxic tissue.

Figure 22. (A) Activation of an exposed Lys residue on Hb with DIBO-NHS by NHS-ester
mediated amidation. (B) PEGylation via strain promoted cycloaddition of activated Hb
Lys residue with the azide PEG where R is the PEG chain/backbone.
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Materials
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Untreated bovine blood was obtained from Animal Technologies (Tyler, TX).
Eight arm N3-PEG was purchased from Creative PEGWorks (Winston Salem, NC).
Sephadex chromatography media were purchased from GE Healthcare Biosciences
(Pittsburg, PA). Micro separatory centrifuge filters (300 kDa) were purchased from
Sartorius Stedim (Bohemia, NY). Hemox Antifoam and the HEMOX oxygen analyzer
were purchased from TCS Scientific (New Hope, PA). DBSF was made by the method
of Zaugg et al (Zaugg, King, Klotz 1975). DIBO-NHS, all other chemicals, and gel
filtration markers kit for protein molecular weights 29 kDa - 700 kDa were
purchased from Sigma-Alrdrich Co. (St. Louis, MO).
Methods
Crosslinked Hemoglobin Synthesis
Methods described by Hanash and Shapiro (Hanash and Shapiro 1981) and
Dozy et al. (Dozy, Kleihauer, Huisman 1968) were modified for the purification of
Hb from bovine blood. Sephadex A-50 gel in 50 mM Tris, 1 mM NaCN, pH 8.5 buffer
was added to centrifuge tubes. Hb was mixed thoroughly with the gel and
centrifuged. The process was repeated three to five times until the supernatant
coming off the gel was still red from Hb. The supernatants were then pooled and
stored in the refrigerator until crosslinking. This method allows for rapid
purification of large quantities of bovine Hb.
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The procedure for crosslinking deoxy-hemoglobin was carried out according
to Walder et al. (Walder et al. 1979). Bis-(3,5-dibromosalicyl)fumarate (DBSF) was
reacted with deoxy-hemoglobin at a mole ratio of 1 Hb: 1.2 DBSF for four hours
under wet nitrogen. The solution was then dialyzed in a 50 mM Tris, 1 mM NaCN, pH
8.5.
Sephadex A-50 was swelled in 50 mM Tris, 1 mM NaCN, pH 8.5 buffer and
poured onto a Kontes Chromaflex column using a decreasing pH gradient. The SDSPAGE protocol was followed according to Schmidt et al. (Schmidt and Brosious
1979) and showed equal intensity bands at 14.4 kDa and 30 kDa.
Reduction of Methemoglobin to Oxyhemoglobin
The procedure used was a modified version of Dixon and McIntosh’s method
(Dixon and McIntosh 1967). A Kontes column, 25 cm x 1.0 cm, was loaded with G-25
gel purchased from GE. The column was then equilibrated with 5 mM Phosphate
Buffered Saline Solution (PBS), pH 7.0, 1 mM EDTA buffer. Following equilibration,
0.2 g of sodium dithionite was added to 2.0 mL of the same buffer, and 0.4-0.6 mL of
this solution was then added to the column followed by addition of 0.2-0.4 mL of the
aforementioned buffer. A 5 mL sample of Hb was then added to the column and
allowed to pass through the gel.
Activation and PEGylation of Alpha Crosslinked Hemoglobin
XL-Hb was dialyzed in 50 mM MOPS, pH 7.2 buffer. The sample was then
passed through a 0.2 micron filter to remove any debris or bacteria. The

concentration of αXL-Hb was determined spectrophotometricaly to activate with
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Dibenzocyclooctyne-N-hydroxysuccinimidyl ester (DIBO-NHS) at a mole ratio of 1
Hb : 1 DIBO-NHS or 1 Hb : 2 DIBO-NHS. The DIBO-NHS was first suspended in dried
DMSO equal to 1% of the total reaction volume before being added to the αXL-Hb.
The reaction was allowed to proceed for two hours at room temperature. Post
activation, the sample was spun in a 30 kDa centrifugal separatory filter (Sartorius
Stedim) at 4000 g and washed with 50 mM MOPS, pH 7.2 to remove any unreacted
DIBO-NHS. The sample was then reacted with the 40 kDa eight arm azide-PEG at a
16 Hb : 1 N3-PEG mole ratio. The reaction continued for one week either at room
temperature or in a refrigerator. Following PEGylation, the PEG XL-Hb solution
was placed in a 300 kDa micro separatory centrifuge filter and spun at 2950 g.
Purification and Verification of PEGylation Alpha Crosslinked Hemoglobin
Concentrated samples, post centrifugation, were run on a pre-packed
Sephacryl S-300 column equilibrated with 50 mM MOPS, pH 7.2 buffer. The large
molecular weight PEGylated XL-Hb fractions were collected and concentrated on a
pre-packed Sephacryl S-500 (GE) for further purification and size determination. A
standard curve was produced for the S-500 column using large molecular weight
markers.
SDS-PAGE Experiments with PEGylated Hemoglobin
A 10 L aliquot of PEG αXL-Hb was added to 10 L of denaturing solution
containing bromophenol blue in an Eppendorf tube. The same volume ratio was
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used to make up αXL-Hb sample and protein marker. The samples were then placed
in a boiling water bath for ten minutes to allow full denaturation. The samples were
loaded on a 12.5% SDS homogenous gel. Following the run, the gel(s) was then
placed in an auto-developer that stained, de-stained, and preserved the SDS gel
(Schmidt and Brosious 1979).
Determination of Molecular Weight via Analytical Ultra Centrifugation (AUC)
AUC was carried out in a Beckman Coulter ProteomeLab XL-A analytical
ultracentrifuge using standard 2 sector cells with quartz windows in 4- or 8-hole
rotors. All sedimentation velocity experiments were at 50,000 rpm with a preset
scan number of 100 per cell. The reference sector was filled with 450 µL of buffer
(50 mM MOPS, .15 M NaCl, pH 7.4) and the sample sector was filled with 430 µL of
sample with an absorbance at 412 nm (1 cm path length) between 0.75 and 1.1.
Buffer density (1.00718 g/mL) was measured at 20.0 C in a Mettler/Paar
Calculating Density Meter DMA 55A and buffer viscosity (0.010543 Poise) was
measured in an Anton Parr AMVn Automated Microviscometer. A partial specific
volume of 0.746 mL/g for bovine hemoglobin was used in calculating molecular
weight (DeMoll et al. 2007). Data were analyzed using the program Sedfit
(www.sedfit.com). Molecular weights and sedimentation coefficients were
determined using the continuous c(s) mode in the sedfit program. Native tetrameric
hemoglobin yielded an s20,w value of 4.25 S which agrees with the accepted value
(Field and O'Brien 1955). The c(s) plots were deconvoluted using nonlinear least-

squares fitting algorithms available in the Origin (v. 9.0) software package
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(OriginLab Corporation, Northapmton, MA). Data were fit to multiple Gaussian
components, increasing the number of components until residual plots (data-fit)
were random and the chi square value for the fit was minimal.
Circular Dichrosim (CD) Secondary Structure characterization of PEG XL-Hb
Circular Dichroism (CD) experiments were carried out on an OLIS DSM 20 CD
Hummingbird Spectrophotometer. Water used to collect base line data was also
used as the dilution solvent for the Hb samples. For each sample a wavelength range
of 180-280 nm was monitored and one data point per nm was collected while
integration time was a function of high volts. The spectra were then smoothed using
Solvitsky Golay 11 point (Whitmore and Wallace 2004; Whitmore and Wallace
2008).
Thermal Denaturation Procedure
Experiments were conducted according to Olsen’s protocol (Olsen 1994).
Experiments were conducted in 10 mM MOPS, 0.9 M guanidine HCl pH 7.0. Samples
were prepared so that the absorbance at 409 nm was between 1 and 1.2. Samples
were monitored every minute on an Agilent 8453 spectrophotometer. A
temperature increase of 0.3C/ min was controlled by Neslab Endocal, Temperature
Programmer ETP-3, and Digital Controller/Readout DCR-4. Absorbance versus
temperature was plotted and the fraction denatured was determined by the
equation FD = (A-AN) / (AD-AN) where A is experimental absorbance, AN is
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absorbance of native protein, and AD is absorbance of denatured protein. AN and AD
were determined by fitting a linear line to the portion of the absorbance versus
temperature plot that corresponded to the effect of temperature on the native or
denatured spectrum respectively. The curve of FD versus temperature was
smoothed in Microsoft Excel.
Autoxidation Experiments
Autoxidation of native, crosslinked, and PEG crosslinked hemoglobin was
carried out according to Yang and Olsen (Yang and Olsen 1989). Hemoglobin
samples were fully reduced and dialyzed in 10 mM MOPS, pH 7.0. Sodium cyanide
was added to each sample and allowed to equilibrate at room temperature for five
minutes prior to data collection. The experiments were conducted at 37C and
allowed to equilibrate before spectra were recorded from 500-700 nm on an Agilent
8453 spectrophotometer.
Oxygen Binding and Determination of P50 and Hill Coefficients
The samples, fully reduced with dithionite, were added to 4.0 mL of 10 mM
MOPS, pH 7.4 and 10 L of Hemox Antifoam and equilibrated to 37 C. Oxygen
binding was determined using a HEMOX Analyzer for native bovine Hb, native Hb
with IHP, XL-Hb, XL-Hb with IHP, and PEG XL-Hb. Hill coefficients (n) and
oxygen affinity (P50) were obtained from Hill plots.

Results
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Crosslinked Hemoglobin (XL-Hb) Production and Purification
Presence of XL-Hb product was verified by SDS-PAGE that showed distinct,
equal intensity bands around 14.4 kDa and 30.0 kDa (Figure 23). The band at 30.0
kDa was indicative of the α monomers covalently linked together by DBSF under
deoxy-conditions while the band at 14.4 kDa was representative of the β monomers.
Confirmation of Large Molecular Weight Species and Separation of PEG XL-Hb from
Unreacted XL-Hb
Figure 23 is the SDS-PAGE gel of the purified PEG XL-Hb sample with a new
band at the origin of the gel. The presence of this band confirmed large molecular
weight species. Figure 24 is a S-300 normalized chromatogram, while Figure 25 is a
chromatogram of the first peak of the S-300 column on a S-500 column. This two
phase separatory system did not resolve the different PEG αXL-Hb species. There
was a noticable separation between the PEGylated and unreacted species. Protein
standards were run, and the elution volume of the PEGylated species resembled that
of apoferritin (MW= 443 kDa) (Fig. 25). The elution volume of the product was used
in tandem with an experimental standard curve that gave a calculated apparent
molecular weight of ~ 500 kDa. This value correlates to a product that has 7 Hb : 1
PEG backbone. Regardless of the DIBO : Hb activation ratio, there were no
differences in the elution volumes of the product.
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Figure 23. SDS-PAGE results of αXL-Hb and PEG αXL-Hb. The αXL-Hb shows
characteristic bands at both 14.4 kDa (β monomers) and 30.0 kDa (XL α monomers).
PEG αXL-Hb shows the same characteristic bands along with the presence of a dark
band at the origin of the gel. Presence of the 14.4 and 30.0 kDa bands in the
PEGylated sample indicate that the activation of Hb via DIBO-NHS and subsequent
PEGylation do not show specificity towards either the α or β monomers of Hb, a
consequence of the high amount of exposed Lys residues.
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Figure 24. S-300 normalized chromatogram. Unreacted XL-Hb eluted around 75
mL while the larger PEG XL-Hb product eluted between 40 and 60 mL.
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Figure 25. An overlay of the chromatograms from S-500 SEC of PEG αXL-Hb (Red),
unreacted αXL-Hb (Blue) and two standards, apoferritin (Black) and thyroglobulin
(Green). An elution volume of 220 mL represents the PEG αXL-Hb sample while an
elution volume of 250 mL is seen for the αXL-Hb sample. A large amount of the
PEGylated product has an apparent molecular weight similar to apoferritin (MW of
443 kDa). However, the broad shouldering on the front side of the column could be
resultant of larger MW species whose apparent weight is lower than that of
thyroglobulin (MW 669 kDa).

80
Size Determination of PEG XL-Hb Samples via Analytical Ultracentrifugation (AUC)
The samples from the S-500 SEC column were analyzed by AUC. Figure 26A
shows three separately prepared samples with a 1:1 DIBO to Hb activation ratio
while Figure 26B is a deconvolution of one of the data sets. It was found that there
were three major high molecular weight PEGylated species. The predominant
species appeared to contain 3-4 Hb tetramers per PEG. Figure 27A shows three
separate PEG αXL-Hb samples that were prepared with a 2:1 DIBO to Hb activation
ratio. The samples were reproducible in their heterogeneity even more so than the
1:1 activation. Figure 27B is a deconvolution of one of the samples. It was found that
there were four large molecular weight PEGylated species, with the predominant
one being 3-4 αXL-Hb tetramers per PEG.

Figure 26. AUC size determination of 1 DIBO : 1 Hb. (A) c(s) versus s20,w plot of three different PEG αXL-Hb.
The samples do not show similar heterogeneity, however the major species for all the samples is 3-4 αXL-Hb
tetramers per PEG backbone. (B) A deconvoluted c(s) versus s20,w plot from one of the samples in figure 26A.
There are three predominant large MW species ranging from 3 to 5 αXL-Hb per PEG backbone.
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Figure 27. AUC data for 2 DIBO : 1 Hb. (A) c(s) versus s20,w for three individual PEG αXL-Hb samples. The samples are
heterogeneous in their speciation but are reproducible in their heterogeneity. (B) A deconvoluted c(s) versus s20,w
plot from one of the samples from figure 27A. There are four large molecular weight species ranging from 3 to 8
αXL-Hb tetramers per PEG backbone. The peak near 2.5S is unconjugated hemoglobin.
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CD Analysis of Secondary Structure in PEG XL-Hb
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CD analysis of the Hb samples showed characteristic signals for alpha helical
secondary structure (Fig 28). The presence of the crosslinker in the central cavity or
a PEG backbone attached to the tetramer did not disrupt the secondary structure.

Figure 28. CD spectra for native Hb (green), αXL-Hb (blue), and PEG αXL-Hb (red). All
three samples show the characteristic signals at 195 nm, 208 nm, and 222 nm.
84

Thermal Denaturation of Hb Samples
Comparison of the fraction denatured curves is shown in Figure 29. The
melting temperatures (Tm) can be found in Table 5. Crosslinking stabilizes the
tetramer compared to native Hb while PEGylation decreases the stability of the
crosslinked species. Experimentally determined Tm values were found to be
statistically significant in their differences through a single factor ANOVA.
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Figure 29. Comparison of fraction denatured curves for native Hb (Blue), αXL-Hb (Red), and PEG
αXL-Hb (Green) that were created by following the absorbance at 409 nm.
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Autoxidation of Hb Samples
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Autoxidation expermients were conducted at 37C to see the effects of
crosslinking and PEGylation on the autoxidation rates at physiological
temperatures. Table 5 contains the relative rate constants (krel) of autoxidation. The
relative rate constants were determined by dividing the slopes of methemoglobin
production for XL-Hb and PEG XL-Hb by the slope of native Hb. It was
determined that crosslinking increased Hb autoxidation rate by 1.78 times and
PEGylation further increased the autoxidative rate to 2.39 times that of native Hb.
Figure 30 shows the spectral changes observed in the PEGylated Hb sample. There
was a decrease in the oxyhemoglobin absorbance at 540 and 576 nm as the sample
autoxidized.
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Figure 30. Autoxidation and spectral changes in PEG XL-Hb sample. The spectra
showed a decrease in absorbance at 576 and 540 nm and an increase of absorbance
at 630 and 510 nm as the sample was allowed to oxidize.
Oxygen Binding Determination of Hb Samples
Figure 31 shows the oxygen binding curves for the three Hb samples. Table 5
presents the experimental P50 values and Hill coefficients (n) that were determined
for native Hb, XL-Hb, and PEG XL-Hb. It was found that XL-Hb had a P50 similar
to that of native Hb within a RBC (P50=27.57). PEG XL-Hb had a slightly lower
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oxygen affinity than XL-Hb with a P50 of 31.97. The difference between the two was
negligible suggesting that inside-out PEGylation did not further affect the oxygen
affinity of XL-Hb. Table 5 also shows that upon crosslinking there was a decrease
in cooperativity as demonstrated by the reduced Hill coefficient. However,
PEGylation did not significantly lower n any further.

Figure 31. Comparison of native Hb (Blue), XL-Hb (Green), and PEG XL-Hb
(Red) oxygen binding curves.
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Table 5. Experimentally determined Tm (C) from fraction denatured curves, relative
rates of autoxidation at 37C (krel), and P50 (torr) and Hill Coefficients determined at
37C for native bovine Hb, αXL-Hb, and PEG αXL-Hb.
Sample

Tm (°C)*

krel

P50 (torr)

Hill Coefficient (n)

Native Hb

41.3 ± .9

1

11.25 ± .17

2.91 ± .06

XL-Hb

53.5 ± .7

1.78 ± .33

27.57 ± 1.36

1.39 ± .01

PEG XL-Hb

46.1 ± .7

2.39 ± .34

31.97 ± 4.48

1.26 ± .04

*ANOVA (F=200.3, Fcrit=5.1)
Discussion
A large inside-out PEG Hb polymer was successfully produced by modifying
exposed Lys residues with a cyclic strained alkyne and PEGylated through copper
free azide-alkyne click chemistry. SDS-PAGE verified crosslinking and PEGylation of
the Hb species (Figure 23). In the XL-Hb sample, the band at 14.4 kDa is the noncrosslinked  subunits while the 30.0 kDa band is the covalently crosslinked 
subunits. These bands were still present in the PEGylated sample with the
concurrent presence of a new band at the origin of the gel. This indicates that the
activation of Hb via DIBO-NHS and subsequent PEGylation does not occur on only
one subunit. This is resultant from the high amount of exposed Lys residues in
bovine Hb. However, the -XL band appears to be lighter in intensity indicating a
slightly higher affinity for modification on the  subunits compared to the 
subunits. It has been previously reported that there are four Lys residues on the 

and  subunits commonly PEGylated; but by contrast, there is a higher affinity for
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the  subunits by comparison (Li et al. 2008).
Large Hb polymers have been found to attenuate stroma free Hb’s
vasoconstrictive properties (Harrington and Wollocko 2011; Martini et al. 2006;
Matheson et al. 2002; Palmer 2006; Palmer and Intaglietta 2014). This is achieved
through increases in the molecular radius and/or hydrodynamic volume. These size
alterations restrict the polymer’s ability to come in contact with the endothelial
lining, as seen in prior, large, non-vasoactive Hb particles (Matheson et al. 2002).
PEG is known to be especially efficacious in achieving these effects. This is resultant
from its highly hydrophilic nature and capacity to bind multiple water molecules per
repeating PEG unit (Hu et al. 2005). A nine-fold increase in hydrodynamic volume
and two-fold increase in molecular radius of PEGylated proteins has been observed
and is not uncommon (Meng et al. 2014; Wang et al. 2014). Inside-out PEGylation
was used to produce such a Hb polymer. Size determination and characterization
were achieved through a two-phase SEC followed by AUC. Separation of XL-Hb and
PEG XL-Hb was observed with S-500 SEC but resolution of the polymeric species
was not seen (Fig. 25). Regardless of DIBO : Hb activation ratios, there were no
differences observed in elution volumes. Furthermore, the elution volume was
identical to that of previously reported inside-out PEGylated proteins generated by
thiol-maleimide click chemistry (Chapter 3). Figure 25 shows the chromatogram of
PEG XL-Hb and known protein standards. The elution volume of the PEGylated
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species resembled that of apoferritin (MW= 443 kDa). According to S-500 SEC, this
molecular weight corresponds to a product that has ~7 Hb : 1 PEG backbone.
However, this is not an accurate representation of the molecular weight but rather
the apparent molecular weight of the polymer in solution. PEG has been shown to
increase a proteins hydrodynamic volume up to nine fold as a result of the PEG’s
ability to retain two to three water molecules per repeating unit (Hu et al. 2005). As
expected, PEGylated proteins appear larger than non-PEGylated standards.
AUC was used to characterize the molecular weight and product speciation. It
was found that PEG XL-Hb generated with a 1:1 DIBO-NHS : Hb molecular ratio
had three predominant large molecular weight species ranging from 3 to 6 αXL-Hb
per PEG backbone (Figure 26). The broad peak in Figure 26B shows the difficulty in
delineating between some of the larger polymers. The major product is around 4 Hb
: 1 PEG backbone. Production of PEG XL-Hb with a 2:1 DIBO-NHS : Hb (Fig. 27)
showed four large molecular weight species ranging from 3 to 8 αXL-Hb tetramers
per PEG backbone with the predominant species being 4 Hb : 1 PEG backbone
(Figure 27B). Comparison of the two samples (Figure 26 and 27) shows that the 1:1
activation produces less speciation than the 2:1 activation but reproducibility in
heterogeneity amongst samples is nearly identical in the 2:1 sample. Moreover, AUC
data for the 2:1 activated product looked similar to prior inside-out PEGylated
polyHb (Chapter 3). Prior inside-out PEGylated polyHb polymers utilized the only
two Cys residues, Cys 93, to conjugate a XL-Hb tetramer onto the PEG backbone.

With the same number of reactive sites to PEGylate compared to the previous
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method, it was expected that azide-alkyne inside-out PEGylation would look similar.
However, the predominant species is 4 Hb : 1 PEG, one tetramer more than prior
products (Chapter 3). Figure 32 is a schematic representation of the major PEG XLHb product. It has been found that larger Hb polymers are unable to scavenge NO in
vivo because they cannot get close enough to the endothelial lining making a larger
Hb nanoparticle more desirable (Matheson et al. 2002; Palmer 2006). Furthermore,
oncotic pressure is relative to the number of particles in solution than the molecular
weights of said components. Thus, larger Hb particles have the potential to reduce
harmful changes in pressor activity upon administration.
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Figure 32. Proposed schematic of Inside-out PEGylated crosslinked hemoglobin. It is
more probable that two arms will bind to a single tetramer than one arm binding to
an individual tetramer. The major inside-out PEGylated hemoglobin polymer
species produced is depicted above (4 Hb : 1 PEG).
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Shown here, inside-out PEG XL-Hb can be classified as both a dendremeric
and poly Hb structure (Kluger and Zhang 2003). In the past poly hemoglobins have
been produced via azide-alkyne copper mediated click chemistry (Foot, Lui, Kluger
2009; Singh et al. 2015b; Yang and Kluger 2010). Conversely, this is the first poly Hb
to be generated without using copper mediation, but rather a cyclic strained alkyne.
With the reaction allowing to proceed without copper, there is no concern of
contamination of the product with an undesirable metal. Other polymeric dimers,
trimers, and octamers of Hb have been generated under different conditions. These
have been created by both chemical modifications and genetic mutations to the Hb
tetramer (Bobofchak et al. 2003; Fablet et al. 2003; Faggiano et al. 2011; Fronticelli
et al. 2001; Vasseur-Godbillon et al. 2006). One of the largest poylmers was around
500 kDa and was shown to not adversly affect blood pressure upon comparision to
crosslinked Hb (Bobofchak et al. 2003). It was infered that this was a result of
decreased extravasation of the compound in circulation. Unfortunately, the
limitations in these approaches are in the amount of genetic mutations and/or
chemical synthesis required to create said products. Cyclic strained mediated azidealkyne inside-out PEGylation makes similar sized Hb polymers with commercially
available reagents. Moreover, the methods presented here can be easily translated
to use for other proteins.
Stroma free Hb dissociates into  dimers in circulation which is readily
filtered out by the kidneys and highly nephrotoxic. Dissociation of the tetramer is

thus circumvented through crosslinking (White and Olsen 1987). The fraction
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denatured curves (Figure 29) show that this modification also increases protein
stability. The melting temperature for XL-Hb has been previously reported and
agrees with the experimentaly determend value presented in this paper (Tm = 53.5
C) (Olsen 1994; White and Olsen 1987; Yang and Olsen 1991). Upon PEGylation,
the stability of the tetramer decreases (Tm = 46.1 C) but is still more stable than
stroma free Hb (Tm = 41.3 C). The observed decrease in Tm was also seen in ealier
inside-out PEGylated Hb polymers (Chapter 3) indicating that crosslinking plays a
larger role affecting Hb properties than PEGylation.
Autoxidation experiments were carried out to assess the speed at which the
Hb samples oxidized at biological temperatures. Within a RBC is a naturally
reducing environment that helps maintain Hb in the functional Fe 2+ state. Upon
extraction from the RBC, Hb more readily oxidizes to the Fe 3+ state. Former studies
have found that crosslinking under deoxy conditions increase the rate of
autoxidation (Yang and Olsen 1989). The data here agrees with those findings and
XL-Hb oxidizes 1.78 times faster than that of stroma free Hb (krel). Following
PEGylation, the rate of oxidation increases to 2.39 times faster than that of stroma
free Hb (Table 5). Figure 30 shows the characteristic spectral changes of the
PEGylated sample as it was allowed to oxidize. Previous studies have shown this
trend in oxidation rates. Acharya and colleagues have previously shown that
PEGylated Hb species oxidize two to three times faster than their unmodified

counterparts (Hu et al. 2008). The increase in krel to PEGylated species has been
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attributed to PEGs water rich nature. When PEG sequesters water molecules it
brings them into closer proximity of the Hb tetramer and allows for an increase in
water mediated oxidation of the iron center. However, when the magnitude of
change is compared following the progression of protein modification, PEGylation
does not increase krel as much as crosslinking. Stroma free Hb to XL-Hb shows an
increased rate of oxidation by 78%, where XL-Hb to PEG XL-Hb shows an
increase of 61% (Table 5). Consequently, the rate of oxidation is affected more so by
crosslinking than modification of the Lys residue and subsequent PEGylation.
Fortunately, it is speculated that the increased rate of oxidation seen at 37 C in vitro
will be less compared to that in vivo due to the antioxidant agents present within
plasma (Hu et al. 2008; Snyder et al. 1987; Yang and Olsen 1989).
Crosslinking not only affects the stability of the Hb tetramer but also oxygen
affinity. Similar CD spectra between Hb samples (Figure 28) elucidated that
differences in oxygen affinity are not correlated with changes in secondary structure
but rather crosslinking protocol. Oxygen binding studies determined that azidealkyne mediated inside-out PEGylation does not influence the oxygen affinity of Hb.
The P50 values (Table 5) show that the crosslinking methodology dictates the
capacity for Hb to bind and release oxygen (PEG XL-Hb P50 = 31.97 torr, XL-Hb
P50 = 27.57 torr). This has been observed in past inside-out PEGylated Hb samples
and is novel to this form of PEGylation (Chapter 3). Traditional PEGylated Hb
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polymers that coat the exterior of Hb with multiple PEG chains have been shown to
increase oxygen affinity independent of PEGylation methodology (Hu et al. 2007; Li
et al. 2008; Li et al. 2009; Lui et al. 2012). Addition of IHP, a 2,3-BPG mimetic, shifted
the oxygen binding curve to the right in all the samples (Walder et al. 1979; Walder,
Walder, Arnone 1980). A shift that lowers oxygen affinity has been previously
reported for XL-Hb and shows that the compound is still accesable to Hb in the
PEGylated product. Decreases in experimentally determined Hill coefficients were
observed post crosslinking and following PEGylation. Cooperativity is reduced if Hb
loses its ability to rotate freely when converting from T to R state upon binding
oxygen. Crosslinking adds a covalent linker in the central cavity restricting the
tetramers rotation, and thus reducing the experimentally determined n seen in
Table 5 (Hb = 2.91, XL-Hb = 1.39). Covalently binding PEG to the XL tetramer
further resticts movement and slightly decreases the cooperativity (PEG XL-Hb n =
1.26). However, this decrease does not affect the oxygen delivery capabilities of the
product. The experimentally determined P50 values of the XL-Hb and PEG XL-Hb
are similar to that of Hb in a RBC. Thus, it is expected that PEG XL-Hb will deliver
oxygen in a nondiscriminatory manner.
Conclusion
We have successfully produced a second inside-out PEGylated Hb complex
through a different combination of crosslinking and PEGylation protocols.
Concurrent application of crosslinking and inside-out PEGylation have the potential
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to mitigate problems seen in previous HBOCs. The oxygen affinity of the product is
similar to that of Hb within a RBC. In addition, this method produced a larger
polymer in comparison to that of thiol-maleimide inside-out PEGylation (Chapter 3).
In theory, the polymer should be able to deliver more oxygen per particle than the
PEG XL-Hb product. With an extra Hb tetramer, on average, covalently linked to the
PEG backbone per particle allows for a higher amount of oxygen to be delivered to
the tissues. Inside-out PEGylation has applications past HBOC development. We
have provided another way to engineer large protein complexes, without the need
for traditional CuAAC. The results reported here promote the versatility that multiarm inside-out PEGylation possesses. Inside-out PEGylation is not restricted to one
method of click chemistry or to a specific protein. We believe that this method of
PEGylation will be effective in the synthesis of other biomacromolecules.

CHAPTER V
FUTURE WORK AND CONCLUSIONS
Future Work
To determine the efficacy of the inside-out PEGylated Hbs as HBOCs, cell
cultures, and/or animal studies need to be conducted. Often, after product
generation and characterization of a new HBOC, animal studies are conducted.
However, cell studies may be more appropriate before testing on an entire
organism. Animal studies are costly and require an immense amount of product.
Before identifying if the product delivers oxygen and/or produces ROS in vivo, it
should be determined whether or not an immune response will be elicited. Ideally,
the first avenue for research to determine this is through cell cultures. In the past
these have not been readily utilized to characterize HBOC products, except a few
that used immunological cells and tissues. These experiments looked at immune
responses induced by the production of cytokines interleukin-6 (IL-6) and tumor
necrosis factor alpha (TNF-) (Zhu et al. 2011). IL-6 is a pro-inflammatory cytokine
and anti-inflammatory myokine, where TNF- stimulates inflammation, apoptotic
cell death, and fever. These cytokines are expressed in myocardial tissue and can be
monitored and quantified with the use of ELISA. If an immune response is
generated, the product will do more harm than good. This can easily be identified
prior to animal studies through this technique.
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In addition, cell studies with HeLa cells should be looked into to evaluate the
products safety prior to animal studies. Cell studies of this nature have not been
utilized in the past to characterize HBOC products. It is my belief that it should be
another standard practice prior to animal studies. This study would be able to
identify if the product will induce cell death, possibly from ROS production.
Furthermore, these studies can be conducted under normoxic and hypoxic
conditions, evaluating any changes in oxygen levels that may be seen in vivo.
Finally, animal studies should be carried out to evaluate HBOC efficacy. This
is usually done by draining blood from the animal, inducing hemorrhagic shock,
then infusing the animal with the HBOC product (Cabrales et al. 2005; Cabrales
2010; Cabrales et al. 2010; Conover et al. 1997; Matsumoto et al. 2005; Raat 2005).
Upon administration, short and long term effects can be monitored. Short term,
damage to the cardiac and vascular tissue can be monitored while examining oxygen
deliver. If the animal is kept alive for longitudinal studies monitor post operatory
conditions such as vascular resistance, kidney damage, gastrointestinal damage, and
recovery times. While these are the first major steps in evaluating human efficacy, it
should be followed by the aforementioned experiments and build upon them.
Conclusions
Presented here are two different inside-out PEGylated Hb polymers that
show potential as blood substitutes. We have shown that this form of PEGylation is
not restricted by the method of conjugation chemistry as seen by its success with
thiol-maleimide and azide-alkyne click chemistry. Inside-out PEGylation does not
alter the secondary structure of the protein while making it more stable by
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comparison to the unmodified protein. Although the products are heterogeneous,
their heterogeneity is reproducible amongst sample preparations. Both products are
large enough in size where they should not be able to interact deleteriously in
circulation with endothelial tissue. However, each product has very different oxygen
delivery characteristics. The PEG XL-Hb sample would release oxygen to highly
hypoxic tissue where a PEG XL-Hb would deliver oxygen in a non-discriminatory
fashion, similar to that of Hb in RBCs.
A viable alternative to current blood transfusions has been actively pursued
for several decades with minimal success. A limited supply of blood, dependent on
human donors, has demanded the creation of a hemoglobin-based oxygen carrier
(HBOC) from non-human sources. Such a product would deliver oxygen to tissues,
providing a therapeutic response to hemorrhagic trauma. However, an effective
HBOC has a utility that exceeds applications in hemorrhagic shock responses. It
may also be used to treat carbon monoxide poisoning, acute anemia, organ ischemia,
and cardioplegia—all conditions related to oxygen deprivation. With a myriad of
potential applications, my research is centered on alleviating the dependence on
human blood donations.
Blood donations must be tested for blood borne pathogens such as HIV. In
The United States of America and other developed countries, testing is not
exceedingly taxing but does take time and decrease the potential pool for donations.
However, in less developed countries where money and testing supplies are limited,
the necessity of a sustainable alternative to blood donations that is disease free
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cannot be understated. Countries where HIV is more predominant already have a
diminished pool to draw on for donations and our product would hopefully be able
to supplement the donations, and most importantly, be produced at a minimal cost.
The research maintains the idea that for the product to be viable from a production
standpoint, it must be relatively simple and inexpensive to produce. The chemistry
used herein to create potential HBOCs is affordable and generated from
commercially available reagents that can be scaled up for mass production.
In addition to the aforementioned reasons to produce a blood substitute, the
product will ideally ameliorate the need for mass blood donations in times of
natural disasters or crisis. When such a disaster occurs that leads to a large
population in need of blood transfusions, our product would be available in a supply
greater than the available—and finite—supply of current blood transfusions. My
work has the potential to provide the global community with the therapeutic
potential to respond liberally to hemorrhagic trauma and other conditions of oxygen
deprivation. The short and long term goals of the project address the viability of this
HBOC, making it a truly successful product, focusing on both efficacy and practicality
of production. Such a substitute has the potential to fill a great need in human health
and bridge an economic divide to the costly alternative treatments that are
currently available.
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